

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE

**Curriculum Vitae - SUMMARY Page - Neil M. Bressler, M.D.**

---

**Title:** The James P. Gills (inaugural) Professor of Ophthalmology – Johns Hopkins University School of Medicine; Past Chief (2005-2018), Retina Division – The Wilmer Eye Institute – Johns Hopkins Hospital

**Peer-Reviewed Publications:** 409

**Major Research:** Design and implement clinical trials evaluating retinal diseases.

- Previously, *Chair* and Principal Investigator of numerous multicenter randomized clinical trials including over 20 sponsored by the National Eye Institute of the National Institutes of Health and several by industry, including Chair of the Diabetic Retinopathy Clinical Research Network 2006 to 2012.
- Currently, *Past Network Chair* of the Diabetic Retinopathy Clinical Research Network (DRCR.net) since 2013, involving over 20 randomized clinical trials and observation studies with over 100 community-based and university-based and community-based sites, sponsored by the National Institutes of Health.

**Educational Roles:**

- Fellowship, residency, and medical student programs in retina at Johns Hopkins
- Director: Numerous annual Continuing Medical Education Courses at Hopkins

**Administrative Role:**

- Past Chief, Retina Division, Wilmer Eye Institute, Department of Ophthalmology, Johns Hopkins University School of Medicine (18 full-time retina physicians; additional basic science faculty; over 50 clinical staff; over 40 research staff) from 2005 to 2018
- Past Chair, Dean's Committee on Outside Interests (including management of financial conflicts of interest)
- Past Chair, School of Medicine Continuing Medical Education Advisory Board

**Clinical Practice:** National and international referral for retinal diseases

**Current Editorial Boards:** *JAMA Ophthalmology* (Editor-in-Chief); *The JAMA Network*

**Current and Past Major National Advisory Roles:**

- *Chair*, Data and Safety Monitoring Committee, National Eye Institute Intramural Program of NIH
- Ophthalmic Devices Panel of the Medical Devices Advisory Committee to the FDA (Past Chair, 2008)
- Observational Study Monitoring Board: Epidemiology of Diabetes Interventions & Complications (EDIC)
- Past President – Macula Society

**Selected Honors:**

- The Macula Society Rosenthal Award and Lecture
- The Society of Heed Fellows Award
- Inaugural Recipient of the Neil R. Miller Medical Student Teaching Award
- The Alvaro Rodriguez Gonzalez Lecture and Gold Medal
- National Society of Southern Dames Award
- The Macula Society J. Donald M. Gass Medal
- American Society of Retinal Specialists Honor Award
- Helen Keller Foundation Award and Lecture
- The Macula Society Research and Education Award
- American Academy of Ophthalmology Senior Achievement Award
- American Society of Retina Specialists Gertrude Pyron Award
- American Academy of Ophthalmology Secretariat Award
- 2009 Healthnetwork Foundation Service Excellence Awards
- Silver Fellow in the ARVO Fellows Class of 2009
- Gold Fellow in the ARVO Fellows Class of 2010
- Research to Prevent Blindness Senior Scientific Investigator Award 2011
- 2014 American Academy of Ophthalmology Life Achievement Honor Award
- 2017 Inaugural International Award and Lecture: Asia Pacific Vitreoretinal Society
- 2018 American Academy of Ophthalmology Secretariat Award

## **BIOGRAPHICAL INFORMATION**

*Born:* New Jersey; USA

*Office Address:* Maumenee 752 – Johns Hopkins Hospital  
600 N. Wolfe Street  
Baltimore, MD 21287-9277  
Phone: +1-1-410-955-8342  
FAX: +1-410-955-0845  
E-mail: [nmboffice@jhmi.edu](mailto:nmboffice@jhmi.edu)

---

## **EDUCATION**

*Undergraduate:* University of Michigan, Ann Arbor, MI - Bachelor of Science - 1978

*Medical School:* The Johns Hopkins University School of Medicine, Baltimore, MD - 1982

*Internship/Internal Medicine Fellowship:* Johns Hopkins Hospital - Department of Medicine - 1982-1983

*Ophthalmology Residency:* Harvard Medical School and Massachusetts Eye and Ear Infirmary, Boston, MA - 1983-1986

*Retinal Fellowship:* Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD - 1986-1987

---

## **ACADEMIC APPOINTMENTS**

July 1, 1987 – June 30, 1988: Harvard Medical School, Department of Ophthalmology, Instructor of Ophthalmology

July 1, 1988 – October 1991: Johns Hopkins University School of Medicine, Department of Ophthalmology, Assistant Professor of Ophthalmology

October 1991 – June 1997: Johns Hopkins University School of Medicine, Department of Ophthalmology, Associate Professor of Ophthalmology

July 1997 – Present: Johns Hopkins University School of Medicine, Department of Ophthalmology, Professor of Ophthalmology

April 2000 – Present: Johns Hopkins University School of Medicine, Department of Ophthalmology, The James P. Gills Professor of Ophthalmology (inaugural recipient)

---

## **PRIMARY HOSPITAL APPOINTMENTS**

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

July 1, 1987 – June 30, 1988: Massachusetts Eye and Ear Infirmary, Assistant in Ophthalmology

July 1, 1988 – October, 1991: Johns Hopkins Hospital, Assistant Professor of Ophthalmology

October 1991 – June 1997: Johns Hopkins Hospital, Department of Ophthalmology, Associate Professor of Ophthalmology

June 1997 – Present: Johns Hopkins Hospital, Department of Ophthalmology, Professor of Ophthalmology

---

**BOARD CERTIFICATIONS**

Ophthalmology - October 27, 1987

---

**HONORS**

1975-78: Class Honors - University of Michigan  
1978: Angell Scholar - University of Michigan  
1978: Bachelor of Science with High Distinction and Honors in Zoology  
1978: Phi Beta Kappa  
1982: Paul Ehrlich Award in Clinical Investigation - Johns Hopkins Medical School  
1986: Heed Fellowship  
1987: Heed/Knapp Fellowship  
1993: American Academy of Ophthalmology Honor Award  
1995: Research to Prevent Blindness Olga Keith Weiss Scholars Award  
1997: The Macula Society Rosenthal Award and Lecture  
1999: The Society of Heed Fellows Award  
2000: Inaugural Recipient of the Neil R. Miller Medical Student Teaching Award  
2000: Inaugural Recipient of the James P. Gills Professorship of Ophthalmology  
2000: National Society of Southern Dames Award  
2001: The Alvaro Rodriguez Gonzalez Lecture and Gold Medal  
2001: Saudi Ophthalmology Society Medal  
2003: The Macula Society J. Donald M. Gass Medal  
2003: Neil R. Miller Medical Student Teaching Award  
2003: American Society of Retinal Specialists Honor Award  
2004: Helen Keller Foundation Award and Lecture  
2004: The Macula Society Research and Education Award  
2004: The American Academy of Ophthalmology's Senior Achievement Award  
2008: The American Academy of Ophthalmology's Secretariat Award  
2008: The American Society of Retina Specialists Gertrude Pyron Award  
2008: American Academy of Ophthalmology Secretariat Award  
2009: Healthnetwork Foundation Service Excellence Awards  
2009: Silver Fellow in the ARVO Fellows Class of 2009  
2010: Gold Fellow in the ARVO Fellows Class of 2010  
2011: Research to Prevent Blindness Senior Scientific Investigator Award  
2014: American Academy of Ophthalmology Life Achievement Honor Award  
2017: Inaugural International Award and Lecture: Asia Pacific Vitreoretinal Society  
2018: The American Academy of Ophthalmology's Secretariat Award

## **PATENTS**

**Neil Bressler, Owings Mills, MD US**

<b>Patent application number</b>	<b>Description</b>	<b>Published</b>
20110242306	<a href="#"><u>SYSTEM AND METHOD FOR AUTOMATED DETECTION OF AGE RELATED MACULAR DEGENERATION AND OTHER RETINAL ABNORMALITIES</u></a> - A system and method for automated detection of age related macular degeneration and other retinal abnormalities which may have a retinal scanner capable of obtaining retinal data from a subject. The retinal scanner may be coupled to a central processing unit (CPU) which may have memory storing CPU-executable instructions which may detect retinal abnormalities. When the CPU receives retinal data from the retinal scanner, the system may perform CPU-executable instructions for detecting retinal abnormalities. The system may analyze the retinal data to determine one or more healthy areas and, based on the analyzed healthy area, the system may detect abnormalities in the retinal data.	10-06-2011

---

## **PEER-REVIEWED PUBLICATION**

1. Bressler NM, Broekman MJ, Marcus AJ. Concurrent studies of oxygen consumption and aggregation in stimulated human platelets. *Blood* 1979;53:167-78.
2. Bressler SB, Bressler NM, Fine SL et al. Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. *Am J Ophthalmol* 1982;93:157-63.
3. Fine SL, Bressler NM, Bressler SB, Murphy RP. Macular degeneration update 1983. *Trans Pac Coast Oto-Ophthalmol Soc* 1982;63:35-40.
4. Bressler SB, Bressler NM, Fine SL et al. Subfoveal neovascular membranes in senile macular degeneration: Relationship between membrane size and visual prognosis. *Retina* 1983;3:7-11.
5. Bressler NM, Gragoudas ES. Neovascularization of the optic disk associated with atypical retinitis pigmentosa. *Am J Ophthalmol* 1985;100:431-33.
6. Bressler NM, Gragoudas ES. Retinitis pigmentosa and retinal neovascularization. *Ophthalmology* 1987;94:895.

**NEIL M. BRESSLER, M.D.**

CURRICULUM VITAE – December 28, 2018

7. Bressler NM, Bressler SB, Gragoudas EG. Clinical characteristics of choroidal neovascular membranes. *Arch Ophthalmol* 1987;105:209-13.
8. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. *Surv Ophthalmol* 1988;32:375-413.
9. Bressler SB, Bressler NM, Seddon JS, et al. Interobserver and intraobserver reliability in the clinical classification of drusen. *Retina* 1988;8:102-08.
10. Bressler NM, Bressler SB, Seddon JS et al. Drusen characteristics in patients with exudative versus non-exudative age-related macular degeneration. *Retina* 1988;8:109-14.
11. Bressler NM, Frost L, Bressler SB, Fine SL. Natural course of poorly defined choroidal neovascularization in macular degeneration. *Arch Ophthalmol* 1988;106:1537-42.
12. Bressler NM, Bressler SB, West SK, Fine SL, Taylor HR. The grading and prevalence of macular degeneration in Chesapeake Bay watermen. *Arch Ophthalmol* 1989;107:847-52.
13. Sunness JS, Massof RW, Bressler NM, Bressler SB. Diminished foveal sensitivity may predict the development of advanced age-related macular degeneration. *Ophthalmology* 1989;96:375-81.
14. West S, Bressler NM, Bressler SB et al. Exposure to sunlight and other risk factors associated with age-related macular degeneration. *Arch Ophthalmol* 1989;107:875-79.
15. Sunness JS, Massof RW, Bressler NM, Bressler SB. S cone pathway sensitivity in eyes with high risk and low risk drusen characteristics. *Applied Optics* 1989;28:1158-64.
16. Chamberlin JA, Bressler NM, Bressler SB, et al. The use of fundus photographs and fluorescein angiograms in the identification and treatment of choroidal neovascularization in the Macular Photocoagulation Study. *Ophthalmology* 1989;96:1526-34.
17. Macular Photocoagulation Study Group (prepared by Maguire MG, Folk JC, Singerman LJ, Schachat AP, Blackhurst DW, Chamberlin JA, Bressler NM, Fine SL, Hawkins BS, Elman MJ). Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis. *Arch Ophthalmol* 1989;107:344-52.
18. Maguire MG, Folk JC, Singerman LJ, Schachat AP, Blackhurst DW, Chamberlin JA, Bressler NM, Fine SL, Hawkins BS, Elman MJ, Macular Photocoagulation Study Group. Response to Letter: Partial ablation of neovascular membranes involving the fovea. *Arch Ophthalmol* 1989;107:955-56.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

19. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration: results of a randomized clinical trial. *Arch Ophthalmol* 1990;108:816-24.
20. Macular Photocoagulation Study Group. Krypton laser photocoagulation for idiopathic neovascular lesions: results of a randomized clinical trial. *Arch Ophthalmol* 1990;108:832-37.
21. Macular Photocoagulation Study Group (prepared by Maguire MG, Blackhurst DW, Alexander J, Bressler NM, Hawkins BS, Fine SL). Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. *Arch Ophthalmol* 1990;108:825-31.
22. Boldt C, Bressler NM, Fine SL, Bressler SB: Age-related macular degeneration. *Curr Opin Ophthalmol* 1990;1:277-257.
23. Bressler SB, Maguire MG, Bressler NM, Fine SL, Macular Photocoagulation Study Group: Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. *Arch Ophthalmol* 1990;108:1442-47.
24. Bressler NM, Finkelstein D, Sunness J, et al. Retinal pigment epithelial tears through the fovea with preservation of good visual acuity. *Arch Ophthalmol* 1990;108:1694-97.
25. Taylor HR, Muñoz MS, West S, Bressler NB, Rosenthal FS, Bressler SB. Visible light and risk of age-related macular degeneration. *Tr Am Ophth Soc* 1990;88:163-78.
26. Bressler NM, Bressler SB, Alexander J, et al. Loculated fluid: A previously undescribed angiographic finding in macular degeneration. *Arch Ophthalmol* 1991;109:211-15.
27. Repka MX, Bressler NM, D'Anna S. Primate model of macular cysts. *Ophthalmology* 1991;98:535-40.
28. Kwiterovich KA, Fine SL, Maguire MG, Bressler NM, Bressler SB, Murphy RP. Frequency of adverse systemic reactions after fluorescein angiography: Results of a prospective study. *Ophthalmology* 1991;98:1139-42.
29. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy after five years: Results from randomized clinical trials. *Arch Ophthalmol* 1991;109:1109-14.
30. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. *Arch Ophthalmol* 1991;109:1219-31.
31. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. *Arch Ophthalmol* 1991;109:1232-41.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

32. Macular Photocoagulation Study Group (prepared by: Bressler NM, Alexander J, Bressler SB, et al). Subfoveal neovascular lesions in age-related macular degeneration: Guidelines for evaluation and treatment in the Macular Photocoagulation Study. *Arch Ophthalmol* 1991;109:1242-57.
33. Macular Photocoagulation Study Group (prepared by Fine SL, Hawkins BS, Maguire MG, Bressler NM, et al). Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. *Arch Ophthalmol* 1991;109:614-15.
34. Folk JC, Blackhurst DW, Alexander J, Elman MJ, Phillips DA, Macular Photocoagulation Study Group. Pretreatment fundus characteristics as predictors of recurrent choroidal neovascularization. *Arch Ophthalmol* 1991;109:1193-94.
35. Taylor HR, West S, Munoz B, Rosenthal FS, Bressler SB, Bressler NM. The long-term effects of visible light on the eye. *Arch Ophthalmol* 1992;110:99-106.
36. Bressler SB, Silva JC, Bressler NM, Alexander JA, Green WR. Clinicopathologic correlation of occult choroidal neovascularization in age-related macular degeneration. *Arch Ophthalmol* 1992;110:827-32.
37. Lim JI, Bressler NM. Atypical parafoveal telangiectasis with subsequent anterior and posterior segment neovascularization. *Retina* 1992;12:351-54.
38. Lim JI, Bressler NM, Marsh MJ, Bressler SB. Laser treatment of choroidal neovascularization in patients with angioid streaks. *Am J Ophthalmol* 1993;116:414-23.
39. Fine SL, Wood WJ, Isernhagen RD, Singerman LF, Bressler NM, Folk JC, Kimura AE, Fish GE, Maguire MG, Alexander J. Laser treatment for subfoveal neovascular membranes in ocular histoplasmosis syndrome: Results of a pilot randomized clinical trial. *Arch Ophthalmol* 1993;111:19-20.
40. Bressler NM, Alexander J, Hawkins BS, Maguire MG, Fine SL, for the Macular Photocoagulation Study Group. Response to letter: Subfoveal neovascular lesions in age-related macular degeneration. *Arch Ophthalmol* 1993;111:901.
41. Macular Photocoagulation Study Group (prepared by Burgess DB, Hawkins BS, Jefferys JL, Bressler NM, et al). Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. *Arch Ophthalmol* 1993;111:1189-99.
42. Custis PH, Bressler SB, Bressler NM: Laser management of subfoveal choroidal neovascularization. *Curr Opin Ophthalmol* 1993;4:7-18.
43. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: Updated findings from two clinical trials. *Arch Ophthalmol* 1993;111:1200-09.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

44. West S, Vitale S, Hallfrisch J, Munoz B, Muller D, Bressler SB, Bressler NM. Are antioxidants or supplements protective for age-related macular degeneration? *Arch Ophthalmol* 1994;112:222-27.
45. Macular Photocoagulation Study Group. Laser photocoagulation of juxtafoveal choroidal neovascularization: Five-year results from randomized clinical trials. *Arch Ophthalmol* 1994;111:500-09.
46. MacCumber MW, Dastgheib K, Bressler NM, Chan C, Harris M, Fine S, Green WR. Clinicopathologic correlation of the multiple recurrent serosanguineous retinal pigment epithelial detachments syndrome. *Retina* 1994;14:143-52.
47. Schein OD, West S, Munoz B, Vitale S, Maguire MG, Taylor HR, Bressler NM. Cortical lenticular opacification: distribution and location in a longitudinal study. *Invest Ophthalmol Vis Sci* 1994;35:363-66.
48. Edwards MG, Schachat AP, Bressler SB, Bressler NM. Outcome of cataract surgery performed to permit diagnosis, determine eligibility for laser therapy, or perform laser therapy of retinal disorders. *Am J Ophthalmol* 1994;118:440-44.
49. Macular Photocoagulation Study Group (prepared by Maguire MG, Klein ML, Oik RJ, Phillips DA, Alexander J, Javornik NB, Hiner C, Marsh MJ, Bressler NM et al). Persistent and recurrent choroidal neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration. *Arch Ophthalmol* 1994;112:489-99.
50. Pieramici DJ, Bressler NM, Bressler SB, Schachat AP. Choroidal neovascularization in black patients. *Arch Ophthalmol* 1994;112:1043-46.
51. Bressler SB, Jefferys JL, Bressler NM, Alexander J, et al, for the Macular Photocoagulation Study Group. Evaluation of green versus red laser for photocoagulation of subfoveal choroidal neovascularization in the Macular Photocoagulation Study. *Arch Ophthalmol* 1994;112:1176-84.
52. Maguire MG, Fine SL, Folk JC, Bressler NM et al for the Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: The influence of initial lesion size and initial visual acuity. *Arch Ophthalmol* 1994;112:480-88.
53. West SK, Bressler SB, Bressler NM, Vitale S. Are antioxidants or supplements protective for age-related macular degeneration? In reply to letter: *Arch Ophthalmol* 1994;112:730.
54. Bressler NM, Silva JC, Bressler SB, Fine SL, Green WR. Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration. *Retina* 1994;14:130-42.



**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

55. Dyer DS, Bressler SB, Bressler NM. The role of laser wavelength in the treatment of vitreoretinal diseases. *Curr Opin Ophthalmol* 1994;5:35-43.
56. Sykes SO, Bressler NM, Maguire MG, Schachat AP, Bressler SB. Detecting recurrent choroidal neovascularization: comparison of clinical examination with and without fluorescein angiography. *Arch Ophthalmol* 1994;111:1561-66.
57. Macular Photocoagulation Study Group (prepared by Marsh MJ, Fine SL, Alexander J, Schachat AP, Maguire MG, Bressler NM, et al). Laser photocoagulation for neovascular lesions nasal to the fovea associated with ocular histoplasmosis or idiopathic causes. *Arch Ophthalmol* 1995;113:56-61.
58. Maguire MG, Fine SL, Folk JC, Bressler NM, et al. Treatment of subfoveal choroidal neovascularization: In reply to letter. *Arch Ophthalmol* 1995;113:138.
59. Macular Photocoagulation Study Group (prepared by Maguire MG, Alexander J, Bressler NM, Schachat AP). The influence of treatment coverage on the visual acuity of eyes treated with krypton laser for juxtafoveal choroidal neovascularization. *Arch Ophthalmol* 1995;113:190-94.
60. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. *Surv Ophthalmol* 1995;39:367-74.
61. Sunness JS, Bressler NM, Maguire MG. Scanning laser ophthalmoscopic analysis of the pattern of visual loss in age-related geographic atrophy of the macula. *Am J Ophthalmol* 1995;119:143-51.
62. West S, Munoz B, Schein O, Vitale S, Maguire M, Taylor H, Bressler NM. Cigarette smoking and risk for progression of nuclear opacities. *Arch Ophthalmol* 1995;113:1377-80.
63. Bressler NM, Munoz B, Maguire MG, Vitale S, Schein OD, Taylor HR, West S. Five-year incidence and disappearance of drusen and retinal pigment epithelial abnormalities. *Arch Ophthalmol* 1995;113:301-08.
64. Friberg TR, Braunstein RA, Bressler NM, Munson, RS. Sudden visual loss associated with sexual activity. *Arch Ophthalmol* 1995;113:738-742.
65. Bressler NM, Bressler SB. Preventative ophthalmology: Age-related macular degeneration. *Ophthalmology* 1995;102:1206-11.
66. Zimmer-Galler IE, Bressler NM, Bressler SB. Treatment of choroidal neovascularization: updated information from recent Macular Photocoagulation Study Group reports. *Int Ophthalmol Clin* 1995;35:37-57.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

67. Dyer DS, Brant AM, Schachat AP, Bressler SB, Bressler NM. Angiographic features and outcome of questionable recurrent choroidal neovascularization. *Am J Ophthalmol* 1995;120:497-505.
68. Bressler NM. Submacular surgery: Are randomized trials necessary? *Arch Ophthalmol* 1995;113:1557-60.
69. Macular Photocoagulation Study Group (prepared by Wilkinson CP, Hawkins, BS, Javornik NB, Newhouse MM, Keller JA, Bressler NM, et al). Five-year follow-up of fellow eyes of individuals with ocular histoplasmosis and unilateral extrafoveal or juxtafoveal choroidal neovascularization. *Arch Ophthalmol* 1996;114:677-88.
70. Macular Photocoagulation Study Group (prepared by Bressler NM, Marsh MJ, Maguire MG, Alexander J, Phillips DA, et al). Occult choroidal neovascularization: Influence on visual outcome in patients with age-related macular degeneration. *Arch Ophthalmol* 1996;114:400-12.
71. Bressler NM, Bressler SB. Indocyanine green angiography: can it help preserve the vision of our patients? *Arch Ophthalmol* 1996;114:747-49.
72. Jabs DA, Dunn JP, Enger C, Forman M, Bressler NM, Charache P. Cytomegalovirus retinitis and viral resistance: Prevalence of resistance at diagnosis. *Arch Ophthalmol* 1996;114:809-14.
73. Bressler NM, O'Brien TP. Meeting report of the Hawaii '96 meeting. *Arch Ophthalmol* 1996;114:894.
74. Avery RL, Fekrat S, Hawkins BS, Bressler NM. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. *Retina* 1996;16:183-89.
75. Kiri A, Dyer DS, Bressler NM, Bressler SB, Schachat AP. Detection of diabetic macular edema: Nidek 3Dx stereophotography compared with fundus biomicroscopy. *Am J Ophthalmol* 1996;122:654-62.
76. Bressler NM, Maguire MG, Murphy, PL, Alexander J, Margherio R, Schachat AP, Fine SL, Stevens TS, Bressler SB. Macular scatter ("grid") laser treatment of poorly demarcated subfoveal choroidal neovascularization in age-related macular degeneration: Results of a randomized pilot trial. *Arch Ophthalmol* 1996;114:1456-64.
77. Levin L, Bressler NM. The case report: when small is beautiful. *Arch Ophthalmol* 1996;114:1413.
78. Enger C, Jabs DA, Dunn JP, Forman MS, Bressler NM, Margolick JB, Charache P, and the CRVR Research Group. Viral resistance and cytomegalovirus retinitis: design and methods of a prospective study. *Ophthalmic Epidemiol* 1997;4:41-48.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

79. Stevens TS, Bressler NM, Maguire MG, Bressler SB, Fine SL, Alexander J, Phillips DA, Margherio RR, Murphy PL, Schachat AP. Occult choroidal neovascularization in age-related macular degeneration: A natural history of morphologic changes. *Arch Ophthalmol* 1997;115:345-50.
80. Macular Photocoagulation Study Group (prepared by Maguire MG, Bressler SB, Bressler NM, Marsh MJ, Alexander J, Phillips DA, et al). Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. *Arch Ophthalmol* 1997;115:741-47.
81. Pharmacological Therapy for Macular Degeneration Study Group (prepared by Guyer DR, Adamis AP, Yannuzzi LA, Gragoudas ES, Coscas GJ, Brancato R, Bird AC, Soubrane G, Miller J, Bressler NM, Slakter JS, DeRosa J). Interferon Alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration: Results of a prospective randomized placebo-controlled clinical trial. *Arch Ophthalmol* 1997;115:865-782.
82. Bressler NM. Submacular surgery: New information; more questions. *Arch Ophthalmol* 1997;115:1071-72.
83. Sunness JS, Rubin GS, Applegate CA, Bressler NM, Marsh MJ, Hawkins BS, Haselwood D. Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity. *Ophthalmology* 1997;104:1677-91.
84. Sunness JS, Rubin GS, Applegate CA, Haselwood D, Marsh MJ, Bressler NM. Visual function and reading rate in eyes with age-related geographic atrophy of the macula and good visual acuity. *Arch Ophthalmol* 1997;104:1677-91.
85. Loewenstein A, Sunness JS, Bressler NM, Marsh MJ, de Juan E Jr. Scanning laser ophthalmoscope fundus perimetry after surgery for choroidal neovascularization. *Am J Ophthalmol* 1998;125:657-65.
86. deJuan E Jr, Loewenstein A, Bressler NM, Alexander J. Translocation of the retina for management of subfoveal choroidal neovascularization II: A preliminary report in humans. *Am J Ophthalmol* 1998;125:635-46.
87. Schmidt-Erfurth U, Miller JW, Sickenberg M, Bunse A, Laqua H, Gragoudas E, Zografos L, Birngruber R, van den Bergh H, Strong A, Manjuris U, Fsadni M, Lane AM, Piguet B, Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization: Clinical and angiographic examples. *Graefes Arch Clin Exp Ophthalmol* 1998;236:365-74.
88. Bressler NM. Evaluating new imaging techniques in retina. *Arch Ophthalmol* 1998;116: 521-22.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

89. Jabs DA, Enger C, Dunn JP, Forman M, Bressler NM for the CMV Retinitis and Viral Resistance Study Group. Cytomegalovirus retinitis and viral resistance: Ganciclovir resistance. *J Infect Dis* 1998;177:770-73.
90. Rosberger DF, Schachat AP, Bressler SB, Bressler NM. Availability of color fundus photographs from previous visit affects practice patterns for patients with diabetes mellitus. *Arch Ophthalmol* 1998;116:1607-10.
91. Bressler NM. Reviewers, authors, editors: balance of power. *Arch Ophthalmol* 1999;117:524-26.
92. Cheeseman EW Jr, Bressler NM, Hunter DG. Familial exudative vitreoretinopathy associated with monocular axial myopia. *Retina* 1999;19:257-59.
93. Raja SC, Jabs DA, Dunn JP, Fekrat S, Machan CH, Marsh MJ, Bressler NM. Pars planitis: clinical features and class II HLA associations. *Ophthalmology* 1999;106:594-99.
94. Sunness JS, Bressler NM, Tian Y, Alexander J, Applegate C. Measuring geographic atrophy in advanced age-related macular degeneration. *Invest Ophthalmol Vis Sci* 1999;40:1761-69.
95. Sunness JS, Gonzalez-Baron J, Bressler NM, Hawkins BS, Applegate CA. The development of choroidal neovascularization in eyes with the geographic atrophy form of age-related macular degeneration. *Ophthalmology* 1999;106:910-19.
96. Weisz JM, Bressler NM, Bressler SB, Schachat AP. Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract extraction. *Ophthalmology* 1999;106:1656-59.
97. Bressler NM. In Reply to Letter to the Editor by Freeman, Bartsch, Mueller, and Banker. *Arch Ophthalmol* 1999;117:847.
98. Friedman DS, Katz J, Bressler NM, Tielsch JM. Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey. *Ophthalmology* 1999;106:1049-55.
99. Sunness JS, Gonzalez-Baron J, Applegate CA, Bressler NM, Tian YS, Hawkins BS, Barron Y, Bergman A. Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration. *Ophthalmology* 1999;106:1768-79.
100. Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournas CJ, Laqua H, Barbazetto I, Zografos L, Piguet B, Donati G, Lane AM, Birngruber R, van den Berg H, Strong HA, Manjuri U, Gray T, Fsadni M, Bressler NM, Gragoudas E. Photodynamic therapy for choroidal neovascularization due to age-related macular degeneration with verteporfin: results of a single treatment in a phase I and II study. *Arch Ophthalmol* 1999;117:1161-73.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

101. The Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study (AREDS): Natural history study and clinical trial – design implications. AREDS report no. 1. *Control Clin Trials* 1999;20:573-00.
102. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (corresponding author: Bressler NM). Verteporfin (Visudyne™) therapy of subfoveal choroidal neovascularization in age-related macular degeneration. One year results of two randomized clinical trials – TAP report no. 1. *Arch Ophthalmol* 1999;117:1329-45.
103. Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas E, Zografos L, Piguet B, Pournas CJ, Donati G, Lane AM, Birngruber R, van den Berg H, Strong HA, Manjuris U, Gray T, Fsadni M, Fsadni M, Bressler NM. Photodynamic therapy of choroidal neovascularization due to age-related macular degeneration with verteporfin: Results of retreatments in a phase I and II study. *Arch Ophthalmol* 1999;117:1177-87.
104. Bressler NM, Bressler SB. Photodynamic therapy with verteporfin (Visudyne™): Impact on ophthalmology and visual sciences. *Invest Ophthalmol Vis Sci* 2000;41:624-28.
105. The Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study (AREDS): A clinical trial of zinc and Antioxidants. AREDS report No. 2. *J Nutr* 2000;130:1516S-19S.
106. Sickenberg M, Schmidt-Erfurth U, Miller JW, Pournas CJ, Zografos L, Piguet B, Donati G, Laqua H, Barbazetto I, Gragoudas E, Lane AM, Birngruber R, van den Berg H, Strong HA, Manjuris U, Gray T, Fsadni M, Fsadni M, Bressler NM. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks and idiopathic causes. *Arch Ophthalmol* 2000;118:327-36.
107. Bressler SB, Bressler NM. Commentary: Retinopathy in patients with type I diabetes four years after intensive therapy. *Arch Ophthalmol* 2000;118:984-85.
108. The Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration: A case-controlled study in the Age-Related Eye Disease Study (AREDS): AREDS report No. 3. *Ophthalmology* 2000;107:2233-39.
109. Orr PR, Cramer LD, Hawkins BS, Bressler NM. Manifest refraction versus autorefraction for patients with subfoveal choroidal neovascularization. *Invest Ophthalmol Vis Sci* 2000;42:447-52.
110. Submacular Surgery Trials Pilot Study Investigators. Submacular Surgery Trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

neovascularization secondary to age-related macular degeneration I. Ophthalmic outcomes, SST Pilot Study Report No. 1. *Am J Ophthalmol* 2000;130:387-07.

111. Submacular Surgery Trials Pilot Study Investigators. Submacular Surgery Trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration II. Quality of life outcomes, SST Pilot Study Report No. 2. *Am J Ophthalmol* 2000;130:408-18.
112. Bressler NM. Age-related macular degeneration. New hope for a common problem comes from photodynamic therapy. *BMJ* 2000;321:1425-27
113. Dubovy SR, Hairston RJ, Schatz H, Schachat AP, Bressler NM, Finkelstein D, Green WR. Adult-onset foveomacular pigment epithelial dystrophy. Clinicopathologic correlation of three cases. *Retina* 2000;20:638-49.
114. Soubrane G, Bressler NM. Treatment of subfoveal choroidal neovascularization in age-related macular degeneration: Focus on clinical application of verteporfin photodynamic therapy. *Br J Ophthalmol* 2001;85:483-95
115. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (corresponding author: Bressler NM). Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two year results of 2 randomized clinical trials – TAP report no. 2. *Arch Ophthalmol* 2001;119:198-07.
116. Verteporfin In Photodynamic Therapy (VIP) Study Group (corresponding author: Bressler NM). Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: One year results of a randomized clinical trial – VIP report no. 1. *Ophthalmology* 2001;108:841-52.
117. Bressler NM, Hawkins BS, Sternberg P Jr, McDonald HR. Are the Submacular Surgery Trials (SST) still relevant in an era of photodynamic therapy? *Ophthalmology* 2001;108:435-36.
118. Verteporfin in Photodynamic Therapy (VIP) Study Group (corresponding author: Bressler NM). Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two year results of a randomized clinical trial including lesions with occult but no classic neovascularization – VIP report no. 2. *Am J Ophthalmol* 2001;131:541-60.
119. Bressler SB, Bressler NM. Randomized clinical trials in ophthalmology in 2001: Twenty-fifth anniversary of the first publication from the Diabetic Retinopathy Study. *Am J Ophthalmol* 2001;131:503-04.
120. The Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study (AREDS) system for classifying cataracts from photographs: AREDS report no. 4. *Am J Ophthalmol* 2001;131:167-75.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

121. Bressler NM. The impact of photodynamic therapy on the management of age-related macular degeneration. *Saudi J Ophthalmol* 2001;15:1-4.
122. The Age-Related Eye Disease Study Research Group. Risk factors associated with age-related nuclear and cortical cataract: A case-control study in the Age-Related Eye Disease Study: AREDS report no. 5. *Ophthalmology* 2001;108:1400-08.
123. Ladd BS, Solomon SD, Bressler NM, Bressler SB. Photodynamic therapy with verteporfin for choroidal neovascularization in patients with diabetic retinopathy. *Am J Ophthalmol* 2001;132:659-67.
124. The Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: AREDS report no. 6. *Arch Ophthalmol* 2001;119:1417-36.
125. The Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. *Arch Ophthalmol* 2001;119:1417-36.
126. The Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene for age-related cataract and vision loss: AREDS report no. 9. *Arch Ophthalmol* 2001;119:1439-52.
127. Fujii GY, de Juan E Jr, Bressler NM. Vitrectomy surgery for impending macular hole based on optical coherence tomography. *Retina* 2001;21:389-92.
128. Bressler NM. Early detection and treatment of neovascular age-related macular degeneration. *J Am Board Fam Pract* 2002;15:142-52.
129. Verteporfin Roundtable 2000 and 2001 Participants, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators, Verteporfin In Photodynamic Therapy (VIP) Study Group Principal Investigators. Guidelines for using verteporfin (Visudyne®) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. *Retina* 2002;22:6-18.
130. Bressler NM. In response to: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in Photodynamic Therapy Report 2. Letter to Editor. *Am J Ophthalmol* 2002;133:168-69.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

131. Ng EWM, Bressler NM, Boyer DS, de Juan E. Iatrogenic choroidal neovascularization occurring in patients undergoing macular translocation surgery. *Retina* 2002;22:711-18.
132. The Age-Related Eye Disease Study Research Group. The effect of five-year zinc supplementation on serum zinc, serum cholesterol and hematocrit in persons randomly assigned to treatment group in the Age-Related Eye Disease Study: AREDS report no. 7. *J Nutr* 2002;132:697-02.
133. Rubin GS, Bressler NM, Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Effects of verteporfin therapy on contrast sensitivity; results from the Treatment of Age-related Macular Degeneration with Photodynamic therapy (TAP) Investigation: TAP Report No. 4. *Retina* 2002;22:536-44.
134. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Three-year results of an open-label extension of 2 randomized clinical trials –TAP Report No. 5 (Corresponding author: Bressler NM). *Arch Ophthalmol* 2002;120:1307-14.
135. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes – TAP Report No. 3. (Corresponding author: Bressler NM). *Arch Ophthalmol* 2002;120:1443-54.
136. Bressler NM for the Verteporfin in Photodynamic therapy (VIP) Study Group: Author reply to letter to editor. *Ophthalmology* 2002;109:1043-44.
137. Bressler NM. Prognosis for placebo-treated eyes in VIP Report 2: author reply. *Am J Ophthalmol* 2002;133:295-96.
138. Bressler NM, Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: author reply. *Am J Ophthalmol* 2002;133:857-59.
139. Saperstein DA, Rosenfeld PJ, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: One-year results of an uncontrolled, prospective case series. *Ophthalmology* 2002;109:1499-1505.
140. Yang Y, Vitale S, Ding Y, O'Connell, SR, Alexander J, Bressler NM, Schachat AP, Zeimer R. A comparison of quantitative mapping and stereoscopic fundus photography grading thickness in diabetic eyes with macular edema. *Ophthalmic Surg Lasers Imaging* 2002;34:1.



**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

141. Bressler NM. Commentary: Retinal arteriolar narrowing and risk of coronary heart disease. *Arch Ophthalmol* 2003;121:113-14.
142. Margalit E, Bressler NM. Retinal pigment epithelium tumor-like lesion arising from area of laser photocoagulation. *Arch Ophthalmol* 2003;121:130-31.
143. Bressler NM, Apte RS. Foveal congenital hypertrophy of the retinal pigment epithelium in the setting of geographic atrophy from age-related macular degeneration. *Am J Ophthalmol* 2003;135:120-21.
144. Sawa M, Masahito O, Gomi F, Kusaka S, Tano Y, Bressler NM. Apparent disappearance of choroidal neovascularization after initial photodynamic therapy with verteporfin. *Am J Ophthalmol* 2003;120:1588-90.
145. Submacular Surgery Trials Research Group. Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: Findings in patients with subfoveal choroidal neovascularization — SST report No.1. *Arch Ophthalmol* 2003;121:531-39. [Correction *Arch Ophthalmol* 2003;121:1513.]
146. Verteporfin In Photodynamic Therapy Study Group (Corresponding author: Bressler NM). Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: Two-year results of a randomized clinical trial — VIP report no. 3. *Ophthalmology* 2003;110:667-73.
147. Improvement After Verteporfin Therapy Writing Committee for the TAP Study Group. Improvement after verteporfin therapy. *Arch Ophthalmol* 2003;121:415-16.
148. Japanese Age-related Macular Degeneration Trial (JAT) Study Group. Japanese Age-related Macular Degeneration Trial (JAT): One-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. *Am J Ophthalmol* 2003;136:1049-61.
149. Mimouni KF, Bressler SB, Bressler NM. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in children. *Am J Ophthalmol* 2003;135:900-02.
150. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change from baseline with and without verteporfin therapy in choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1 (Corresponding author: Bressler NM). *Am J Ophthalmol* 2003;136:407:18.
151. Clemons TE, Chew EY, Bressler SB, McBee W, for the AREDS Research Group. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS). AREDS report no. 10. *Arch Ophthalmol* 2003;121:211-17.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

152. Diloreto DA, Bressler NM, Bressler SB, Schachat AP. Use of best and final visual acuity outcomes in ophthalmologic research. *Arch Ophthalmol* 2003;121:1586-90.
153. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy Study Groups. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: Fluorescein angiographic guidelines for evaluation and treatment – TAP and VIP Report no. 2. *Arch Ophthalmol* 2003;121:1253-68.
154. The Age-Related Eye Disease Study Research Group. Potential public health impact of AREDS results: AREDS Report No. 11. *Arch Ophthalmol* 2003;121:1621-24.
155. Hubbard LD, Ricks MO, Martin BK, Bressler, Kempen JH, Dunn JP, Jabs DA. Comparability of two fundus photographs reading centers in grading CMV retinitis progression. *Am J Ophthalmol* 2004;137:426-34.
156. Subramanian PS, Bressler NM, Miller NR. Radiation retinopathy after fractionated stereotactic radiotherapy for optic nerve sheath meningioma. *Ophthalmology* 2004;111:565-67.
157. Do DV, Bressler, NM, Bressler SB. Large submacular hemorrhages after verteporfin therapy. *Am J Ophthalmol* 2004;137:558-60.
158. Submacular Surgery Trials Pilot Research Group. Responsiveness of the SF-36 health survey to changes in visual acuity amount patients with subfoveal choroidal neovascularization. *Am J Ophthalmol* 2004;137:373-75.
159. Miskala PH, Bressler NB, Meinert CL. Is adjustment of NEI-VFQ scores for general health necessary in randomized trials? *Am J Ophthalmol* 2004;137:961-63.
160. Submacular Surgery Trials Research Group. Clinical trial performance of community-based compared with university-based practices: Lessons from the Submacular Surgery Trials, SST Report no. 2. *Arch Ophthalmol* 2004;122:857-63.
161. Treatment of Age-related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy Trial Study Groups. Acute severe visual acuity decrease following photodynamic therapy with verteporfin: Case reports from randomized clinical trials – TAP and VIP Report no. 3. *Am J Ophthalmol* 2004;137:683-96.
162. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Natural history of minimally classic subfoveal choroidal neovascular lesions in the Treatment of Age-related macular degeneration with Photodynamic therapy (TAP) Investigation: Outcomes potentially relevant to management – TAP Report no. 6. *Arch Ophthalmol* 2004;122:325-29.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

163. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin In Photodynamic Therapy (VIP) Study Groups. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Meta-analysis of two-year safety results in three randomized clinical trials – TAP and VIP Report no. 4. *Retina* 2004;24:1-12.
164. Diloreto DA, Bressler NM, Goldberg MF. Choroidal neovascularization after central retinal vein occlusion in a 47-year-old man. *Arch Ophthalmol* 2004;122:1398-1401.
165. Brown JC, Solomon SD, Bressler SB, Schachat AP, DiBernardo C, Bressler NM. Detection of diabetic foveal edema: Contact lens biomicroscopy compared with optical coherence tomography. *Arch Ophthalmol* 2004;122:330-35.
166. Miskala PH, Bressler NM, Meinert CI. Relative contributions of reduced vision and general health to NEI-VFQ scores in patients with neovascular age-related macular degeneration. *Arch Ophthalmol* 2004;122:758-66.
167. Bressler NM, Liesegang T, Schachat AP, Albert DM. Advantages and potential dangers of presentation before publication: Third in a series on editorship. *Arch Ophthalmol* 2004;122:1045-48.
168. Rosenfeld PJ, MD, Saperstein DA, Bressler NM, Reaves TA, Sickenberg M, Rosa RH, Sternberg P, Aaberg TM, Verteporfin in Ocular Histoplasmosis (VOH) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: Uncontrolled, open-label 2-year study. *Ophthalmology* 2004;111:1725-33.
169. Blair MP, Apte RS, Miskala PH, Bressler SB, Goldberg MF, Schachat AP, Bressler NM. A retrospective case series of juxtafoveal choroidal neovascularization treated with photodynamic therapy with verteporfin. *Retina* 2004;24:501-6.
170. Submacular Surgery Trials Research Group. Health and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at time of enrollment in randomized trials of submacular surgery: SST Report no. 4. *Am J Ophthalmol* 2004;138:91-108.
171. The Complications of Age-Related Macular Degeneration Prevention Trial Study Group. The Complications of Age-Related Macular Degeneration Prevention Trial (CAPT): Rationale, design, methodology. *Clin Trials* 2004;1:91-107.
172. Bressler NM, Age-related macular degeneration is the leading cause of blindness. *JAMA* 2004;291:1900-01.
173. Age-Related Eye Disease Study Research Group. Impact of antioxidants, zinc, and copper on cognition in the elderly: A randomized, controlled trial. AREDS report no. 12. *Neurology* 2004;63:1705-07.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

174. VAM Study Writing Committee (Corresponding author Bressler NM). Verteporfin therapy in age-related macular degeneration (VAM): An open-label multicenter photodynamic therapy study of 4,435 patients. *Retina* 2004;24:512-20.
175. The Age-Related Eye Disease Study Research Group. Association of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study. AREDS Report no. 13. *Arch Ophthalmol* 2004;122:716-26.
176. Submacular Surgery Trials Research Group. Surgical removal versus observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic. I. Ophthalmic findings from a randomized clinical trial: SST Group H Trial. SST Report no. 9. *Arch Ophthalmol* 2004;122:1597-1611.
177. Submacular Surgery Trials Research Group. Surgical removal versus observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic – II. Quality-of-life findings from a randomized clinical trial: SST Group H Trial. SST Report no. 10. *Arch Ophthalmol* 2004;122:1616-28.
178. Submacular Surgery Trials (SST) Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Ophthalmic findings. SST Group N Trial. SST Report no. 11. *Ophthalmology* 2004;111:1967-80.
179. Submacular Surgery Trials (SST) Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Quality of life findings. SST Group N Trial. SST Report no. 12. *Ophthalmology* 2004;111:1981-92.
180. Submacular Surgery Trials (SST) Research Group. Surgery for hemorrhagic choroidal neovascular lesions in age-related macular degeneration: Ophthalmic findings. SST Group B Trial. SST Report no. 13. *Ophthalmology* 2004;111:1993-06.
181. Submacular Surgery Trials (SST) Research Group. Surgery for hemorrhagic choroidal neovascular lesions in age-related macular degeneration: Quality-of-life findings. SST Report 14. *Ophthalmology* 2004;111:2007-14.
182. Submacular Surgery Trials Research Group. Patients' perceptions of the value of current vision: Assessment of preference values among patients with subfoveal choroidal neovascularization – the Submacular Surgery Trials Vision Preference Value Scale: SST Report no. 6. *Arch Ophthalmol* 2004;122:1856-67.
183. The Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). *Ophthalmology* 2004;111:1307-16.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

184. Sadda SR, Pieramici DJ, Marsh MJ, Bressler NM, Bressler SB, for the Submacular Surgery Trials Pilot Study Investigators. Changes in lesion size after Submacular Surgery for subfoveal choroidal neovascularization in the Submacular Surgery Trials Pilot Study. *Retina* 2004;24:888-99.
185. VIP Report No. 5 Writing Committee. Letter to Editor. Verteporfin in Photodynamic Therapy: Report no. 5. *Ophthalmology* 2004;111:2144.
186. Responsiveness of the NEI-VFQ to progression to advanced AMD, vision loss, lens opacity, and cataract surgery. AREDS Report No. 14. *Arch Ophthalmol* 2004;123:1201-06.
187. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS). AREDS Report No. 19. *Ophthalmology* 2005;112:533-39.
188. Schein OD, Bressler NM, Price P. Photodynamic therapy with verteporfin. Observations on the introduction of a new treatment into clinical practice. *Arch Ophthalmol* 2005;123:58-63.
189. Submacular Surgery Trials Research Group. Health and vision-related quality of life among patients with ocular histoplasmosis or idiopathic choroidal neovascularization at time of enrollment in a randomized trial of submacular surgery. SST Report no. 5. *Arch Ophthalmol* 2005;123:78-88.
190. Submacular Surgery Trials Research Group. Effect of order of administration of health-related quality of life interview instruments on responses: SST Report no. 3. 2005; *Qual Life Res* 2005;14:493-00.
191. Submacular Surgery Trials (SST) Research Group. Histopathological and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions: SST Report no. 7. *Arch Ophthalmol* 2005;123:914-21.
192. Submacular Surgery Trials (SST) Research Group. Guidelines for interpreting retinal photographs in the Submacular Surgery Trials (SST): SST Report No. 8. *Retina* 2005;25:253-68.
193. Verteporfin Roundtable 2003 Participants. Guidelines for using verteporfin (Visudyne®) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. *Retina* 2005;25:119-34.
194. Bressler NM. Cystoid macular edema from niacin typically is not accompanied by fluorescein leakage on angiography (Letter to Editor). *Am J Ophthalmol* 2005;139:951.
195. Orr PR, Marsh MJ, Hawkins BS, Hawse PL, Bressler NM. Evaluation of the traveling vision examiner program of the Submacular Surgery Trials Pilot Study. *Ophthalmic Epidemiol* 2005;12:47-57.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

196. Visudyne® In Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-Year Results of a Randomized Clinical Trial. *Arch Ophthalmol* 2005;123:448-57.
197. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal Neovascularization in age-related macular degeneration: Four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7. *Arch Ophthalmol* 2005;123:1283-85
198. Bressler SB, Bressler NM. Dick Green Tribute. *Retina* 2005;25:S1-S28.
199. The Macugen Diabetic Retinopathy Study Group. A Phase II randomized, double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer for diabetic macular edema. *Ophthalmology* 2005;112:1747-57.
200. Preferential Hyperacuity Perimeter (PHP) Research Group. Preferential Hyperacuity Perimeter (PreView PHP™) for detecting choroidal neovascularization study. *Ophthalmology* 2005;112:1758-65.
201. Ober MD, Yannuzzi LA, Do DV, Spaide RF, Bressler NM, Jampol LM, Angelilli A, Eandi CM, Lyon AT. Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. *Ophthalmology* 2005;112:2088-94.
202. Bressler NM. Retinal anastomosis to choroidal neovascularization. A bum rap for a difficult disease. *Arch Ophthalmol* 2005;123:1741-03.
203. The Age-Related Eye Disease Study Research Group. The age-related eye disease study severity scale for age-related macular degeneration: AREDS Report No. 17. *Arch Ophthalmol* 2005;123:1484-98.
204. The Age-Related Eye Disease Study Research Group. A simplified severity scale for age-related macular degeneration. AREDS Report No. 18. *Arch Ophthalmol* 2005;123:1570-74.
205. Submacular Surgery Trials (SST) Research Group. Comparison of 2-dimensional reconstructions of surgically-excised choroidal neovascularization with fluorescein angiographic features: SST Report No. 15. *Ophthalmology* 2006;113:267–79.
206. Verteporfin In Photodynamic Therapy (VIP) Study Groups. Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: Clinically relevant natural history information in larger lesions with good vision from the verteporfin in photodynamic therapy (VIP) Trial - VIP Report No. 4. *Arch Ophthalmol* 2006;124:660-64.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

207. Macugen Diabetic Retinopathy Study Group. Changes in retinal neovascularization following pegaptanib (Macugen) therapy in diabetic individuals. *Ophthalmology* 2006;113:23-28.
208. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of 2 randomized clinical trials with an open-label extension—TAP Report No. 8. *Graefe's Arch Clin Exp Ophthalmol* 2006;244:1132-42.
209. The Age-Related Eye Disease Study Research Group. Cognitive impairment in the age-related eye disease study. AREDS Report No. 16. *Arch Ophthalmol* 2006;124:537-43.
210. The Age-Related Eye Disease Study Research Group. Centrum use and progression of age-related cataract in the age-related eye disease study. AREDS report no. 21. *Ophthalmology* 2006;113:1264-70.
211. Do DV, Nguyen QD, Bressler NM, Schachat AP, Solomon SD, Melia M, Bressler SB. Hemoglobin A1C awareness among patients receiving eye care at a tertiary ophthalmic center. *Am J Ophthalmol* 2006;141:951-53.
212. Submacular Surgery Trials (SST) Research Group. Clinicopathologic studies of eyes obtained post-mortem from four patients enrolled in the Submacular Surgery Trials: SST Report No. 16. *Am J Ophthalmol* 2006;141:93-04.
213. Kim SJ, Equi R, Bressler NM. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. *Ophthalmology* 2007;114:881-9.
214. Fong DS, Bressler NM. Comparison of modified-ETDRS and mild macular grid laser photocoagulation strategies for diabetic macular edema. *Arch Ophthalmol* 2007;125:469-80.
215. Submacular Surgery Trials (SST) Research Group. Comparison of methods to identify incident cataract in eyes of patients with neovascular maculopathy: SST Report no. 18. *Ophthalmology* 2006;115:127-33.
216. Diabetic Retinopathy Clinical Research Network. Diurnal variation in retinal thickening measurement by OCT in center-involved diabetic macular edema. *Arch Ophthalmol* 2006;124: 1701-07.
217. Diabetic Retinopathy Clinical Research Network. A randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: A pilot study. *Ophthalmology* 2007;114;1190-96.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

218. Diabetic Retinopathy Clinical Research Network. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. *Ophthalmology* 2007;114:525-36.
219. Diabetic Retinopathy Clinical Research Network. Comparison of modified-Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. *Arch Ophthalmol* 2007;125:469-80.
220. Submacular Surgery Trials (SST) Research Group. Incident choroidal neovascularization in fellow eyes of patients with unilateral subfoveal choroidal neovascularization secondary to age-related macular degeneration: SST Report no. 20. *Arch Ophthalmol* 2007;125:1323-30.
221. Sunness JS, Margalit E, Srikumaran DG, Applegate CA, Tian Y, Perry D, Hawkins BS, Bressler NM. The long-term natural history of geographic atrophy from age-related macular degeneration: Enlargement of atrophy and implications for interventional clinical trials. *Ophthalmology* 2007;114:271-77.
222. Beck R, Maguire, Bressler NM, Glassman AR, Lindblad AS, Ferris FL. Visual acuity as an outcome measure in clinical trials of retinal diseases. *Ophthalmology* 2007;114:1804-09.
223. Submacular Surgery Trials (SST) Research Group. Evaluation of minimum meaningful changes in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ) SST report no. 19. *Ophthalmic Epidemiol* 2007;14:205-15.
224. Diabetic Retinopathy Clinical Research Network. A phase 2 randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. *Ophthalmology* 2007;114:1860-67.
225. Bhavsar AR, Ip MS, Glassman AR, for the DRCR.net and the SCORE Study Groups. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCR.net and SCORE clinical trials. *Am J Ophthalmol* 2007;144:454-56.
226. Diabetic Retinopathy Clinical Research Group. Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. *Ophthalmology* 2007;114:1520-25.
227. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration. *Arch Ophthalmol* 2007;125:1460-69.
228. Neovascular Age-Related Macular Degeneration, Periocular Corticosteroids, and Photodynamic Therapy (NAPP) Trial Research Group. Periocular triamcinolone and photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration. *Ophthalmology* 2007;127:1713-21.



**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

229. Virgili G, Do DV, Bressler NM, Menchini U. New therapies for neovascular age-related macular degeneration: critical appraisal of the current evidence. *Acta Ophthalmol Scand* 2007;85:6-20.
230. Chang MA, Fine H, Bass E, Bressler SB, Schachat AP, Solomon SD, Bressler NM. Patients' preferences in choosing therapy for retinal vein occlusions. *Retina* 2007;27:789-97.
231. The Age-Related Eye Disease Study Research Group. Relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS Report No. 23. *Arch Ophthalmol* 2008;126:1274-79.
232. Scott IU, Bressler NM, Bressler SB, Browning DJ, Chan CK, Danis RP, Davis MD, Kollman C, Qin H, and the Diabetic Retinopathy Clinical Research Network Study Group. Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. *Retina* 2008;28:36-40.
233. Sunness JS, Rubin GS, Broman A, Applegate CA, Bressler NM, Hawkins BS. Low luminance visual dysfunction as a predictor of subsequent visual acuity loss from geographic atrophy in age-related macular degeneration. *Ophthalmology* 2008;115:1480-88.
234. Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H and the Diabetic Retinopathy Clinical Research Network Study Group. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. *Ophthalmology* 2008;115:1366-71.
235. Bressler NM, Edwards AR, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Danis RP, Elman MJ, Friedman SM, Glassman AR, Gross JG, Li HK, Murtha TJ, Stone TW, Sun JK on behalf of the Diabetic Retinopathy Clinical Research Network. Retinal thickness on stratus™ optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. *Am J Ophthalmol* 2008;145:894-901.
236. Jeffreys J, Alexander JA, Hiner C, Javornik N, Smith R, Bressler NM, Hawkins BS, Maguire M. Reproducibility of gradings of retinal photographs in eyes with subfoveal choroidal neovascularization and age-related macular degeneration in the macular photocoagulation study. *Ophthalmic Epidemiol* 2008;15:191-01.
237. Davis MD, Bressler SB, Aiello LP, Bressler NM, Browning DJ, Flaxel CJ, Fong DS, Foster WJ, Glassman AR, Hartnett MER, Kollman C, Li HK, Qin H, Scott IU and the Diabetic Retinopathy Clinical Research Network Study Group. Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema. *Invest Ophthalmol Vis Sci* 2008;49:1745-52.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

238. Kim SJ, Belair ML, Bressler NM, Dunn JP, Thorne JE, Kedhar SR, Jabs DA. A method of reporting macular edema after cataract surgery using optical coherence tomography. *Retina* 2008;28:870-76.
239. Ip MS, Bressler SB, Antoszyk AN, Flaxel CJ, Kim JE, Friedman SM, Qin H, and the Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone and laser photocoagulation for diabetic macular edema: Baseline features. *Retina* 2008;28:919-30.
240. Sunness JS, Rubin GS, Broman A, Applegate CA, Bressler NM, Hawkins BS. Low luminance visual dysfunction as a predictor of subsequent visual acuity loss from geographic atrophy in age-related macular degeneration. *Ophthalmology* 2008;115:1480-88.
241. Browning DJ, Altaweel MM, Bressler NM, Bressler SB, Scott IU, and the Diabetic Retinopathy Clinical Research Network. Diabetic macular edema: What is focal and what is diffuse? *Am J Ophthalmol* 2008;146:649-55.
242. Submacular Surgery Trials Research Group. Surgical removal vs observation for idiopathic or ocular histoplasmosis syndrome-associated subfoveal choroidal neovascularization. Vision preference value scale findings from the randomized SST Group H Trial: SST Report No. 17. *Arch Ophthalmol* 2008;126:1626-32.
243. The Age-Related Eye Disease Study Research Group. Cataract classification using serial examinations in the Age-Related Eye Disease Study. AREDS Report No. 24. *Am J Ophthalmol* 2008;145:504-08.
244. Charkoudian LD, Gower EW, Solomon SD, Schachat AP, Bressler NM, Bressler SB. Vitamin usage patterns in the prevention of advanced age-related macular degeneration. *Ophthalmology* 2008;115:1032-38.
245. Diabetic Retinopathy Clinical Research Network. Randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. *Ophthalmology* 2008;115:1447-59.
246. Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J for the Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Research Group. Improved vision-related function after ranibizumab vs photodynamic therapy. *Arch Ophthalmol* 2009;127:13-21.
247. Diabetic Retinopathy Clinical Research Network. An observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation (PRP) given in 1 or 4 sittings. *Arch Ophthalmol* 2009;127:132-40.
248. Casparis H, Lindsley K, Bressler NM. Surgery for cataracts in people with age-related macular degeneration. *Cochrane Database of Systematic Reviews* 2009 Issue 1. Art. No.: CD006757. DOI: 10.1002/14651858.CD006757.pub2

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

249. Diabetic Retinopathy Clinical Research Network. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. *Arch Ophthalmol* 2009;127:245-51.
250. Scott IU, Danis RP, Bressler SB, Bressler NM, Browning DJ, Qin H, for the Diabetic Retinopathy Clinical Research Network. Effect of focal/grid photocoagulation on visual acuity and retinal thickening in eyes with non-center involved clinically significant diabetic macular edema. *Retina* 2009;29:613-17.
251. Ip MS, Edwards AR, Beck RW, Bressler NM for the Diabetic Retinopathy Clinical Research Network. Response to Letters to the Editor Regarding "A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema". *Ophthalmology* 2009;116:1228-29.
252. Suñer IJ, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM. NEI VFQ-25 is responsive to changes in visual acuity in neovascular AMD: Results of validation studies using data from 2 phase 3 clinical trials. *Invest Ophthalmol Vis Sci* 2009;50:3629-35.
253. Hawkins BS, Bressler NM, Reynolds SM. Visual acuity outcomes among sham versus no-treatment controls from randomized trials. *Arch Ophthalmol* 2009;127:725-31.
254. Bhavsar AR, Googe JM, Stockdale CR, Bressler NM, Brucker AJ, Elman MJ, Glassman AR for the Diabetic Retinopathy Clinical Research Network. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: The Diabetic Retinopathy Clinical Research Network laser-ranibizumab-triamcinolone clinical trials. *Arch Ophthalmol* 2009;127:1581-83.
255. Dong LM, Stark WJ, Jefferys JL, Al-Hazzaa S, Bressler SB, Solomon SD, Bressler NM. Progression of age-related macular degeneration after cataract surgery. *Arch Ophthalmology* 2009;127:1412-19.
256. Bressler NM, Edwards AR, Beck RW, Flaxel CJ, Glassman AR, Ip MS, Kollman C, Kuppermann B, Stone T for the Diabetic Retinopathy Clinical Research Network. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. *Arch Ophthalmol* 2009;127:1566-71.
257. Submacular Surgery Trials (SST) Research Group. Risk factors for rhegmatogenous retinal detachment in the Submacular Surgery Trials: SST Report No. 22. *Retina* 2009;29:819-24.
258. Aiello LP, Edwards AR, Beck RW, Bressler NM, Davis MD, Ferris F, Glassman AR, Ip MS, Miller KM for the Diabetic Retinopathy Clinical Research Network. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. *Ophthalmology* 2010;117:946-53.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

259. Gower EW, Cassard SD, Bass EB, Schein OD, Bressler NM. A cost-effectiveness analysis of three treatments for age-related macular degeneration. *Retina* 2010;30:212-21.
260. Bressler NM, Chang TS, Suñer IJ, Fine JT, Dolan CM, Ward J, Ianchulev T for the MARINA and ANCHOR Research Groups. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. *Ophthalmology* 2010;117:747-56.
261. Hawkins BS, Bressler NM, Reynolds SM: Patient-reported outcomes among sham versus no-treatment controls from randomized trials. In reply to letter: *Arch Ophthalmol* 2010;128:648.
262. Diabetic Retinopathy Clinical Research Network. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3<sup>rd</sup>, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology* 2010;117:1064-77.
263. Diabetic Retinopathy Clinical Research Network Writing Committee on behalf of the DRCR.net. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. *Ophthalmology* 2010;117:1087-93.
264. Chang MA, Do DV, Bressler SB, Cassard SD, Gower EW, Bressler NM. Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration. *Retina* 2010;30:1171-76.
265. Flaxel CJ, Edwards AR, Aiello LP, Arrigg PG, Beck RW, Bressler NM, Bressler SB, Ferris FL 3<sup>rd</sup>, Gupta SK, Haller JA, Lazarus HS, Qin H, The Diabetic Retinopathy Clinical Research Network. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema. *Retina* 2010;30:1488-95.
266. Bhavsar AR, Stockdale CR, Bressler NM for the Diabetic Retinopathy Clinical Research Network. Topical antibiotics to reduce the risk of endophthalmitis after intravitreal injection?—Reply. *Arch Ophthalmol* 2010;128:1223-24.
267. Khurana RN, Dupas B, Bressler NM. Agreement of time-domain and spectral-domain optical coherence tomography with fluorescein leakage from choroidal neovascularization. *Ophthalmology* 2010;117:1376-80.
268. Bressler NM, Schachat AP. Management of macular edema from retinal vein occlusions: you can never have too many choices. *Ophthalmology* 2010;117:1061-63.
269. Danis RP, Scott IU, Qin H, Altaweel MM, Bressler NM, Bressler SB, Browning DJ, Kollman C; Diabetic Retinopathy Clinical Research Network. Association of fluorescein angiographic features with visual acuity and with optical coherence

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

tomographic and stereoscopic color fundus photographic features of diabetic macular edema in a randomized clinical trial. *Retina* 2010;30:1627-37.

270. Geitzenauer W, Kiss CG, Durbin MK, Abunto MT, Callan TM, Stetson PF, Wieland MR, Bressler NM, Gregori G, Schmidt-Erfurth UM. Comparing retinal thickness measurements from Cirrus spectral-domain and Stratus time domain-optical coherence tomography. *Retina* 2010;30:596-06.
271. Varma R, Richman EA, Ferris FL 3<sup>rd</sup>, Bressler NM. Use of patient-reported outcomes in medical product development: a report from the 2009 NEI/FDA Clinical Trial Endpoints Symposium. *Invest Ophthalmol Vis Sci* 2010;51:6095-03.
272. Hawkins BS, Bressler NM, Reynolds SM. Patient-reported outcomes among sham vs no-treatment controls from randomized trials. *Arch Ophthalmol* 2011;129:200-05.
273. Burlina P, Freund DE, Dupas B, Bressler NM. Automatic screening of age-related macular degeneration and retinal abnormalities. *Conf Proc IEEE Eng Med Biol Soc* 2011;2011:3962-66.
274. Diabetic Retinopathy Clinical Research Network; Writing Committee, Aiello LP, Beck RW, Bressler NM, Browning DJ, Chalam KV, Davis M, Ferris FL 3<sup>rd</sup>, Glassman AR, Maturi RK, Stockdale CR, Topping TM. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. *Ophthalmology* 2011;118:e5-14.
275. Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3<sup>rd</sup>, Friedman SM, Glassman AR, Scott IU, Stockdale CR, Sun JK; Diabetic Retinopathy Clinical Research Network. Expanded 2-Year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology* 2011;118:609-14.
276. Sun JK, Aiello LP, Cavallerano JD, Stockman M, Miller KM, Qin H, Beck RW, Glassman AR for the Diabetic Retinopathy Clinical Research Network. Visual acuity testing using autorefraction or pinhole occluder compared with a manual protocol refraction in individuals with diabetes. *Ophthalmology* 2011;118:537-42.
277. Bressler NM, Doan QV, Varma R, Lee PP, Suñer IJ, Dolan C, Danese MD, Yu E, Tran I, Colman S. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. *Arch Ophthalmol* 2011;129:709-17.
278. Chew EY, Glassman AR, Beck RW, Bressler NM, Fish GE, Ferris FL, Kinyoun JL; Diabetic Retinopathy Clinical Research Network. Ocular side effects associated with peribulbar injections of triamcinolone acetonide for diabetic macular edema. *Retina* 2011;31:284-09.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

279. Diabetic Retinopathy Clinical Research Network, Googe J, Brucker AJ, Bressler NM, Qin H, Aiello LP, Antoszyk A, Beck RW, Bressler SB, Ferris FL 3<sup>rd</sup>, Glassman AR, Marcus D, Stockdale C. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. *Retina* 2011;31:1009-27.
280. Orr PR, Rentz AM, Margolis MK, Revicki DA, Dolan CM, Colman S, Fine JT, Bressler NM. Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in age-related macular degeneration. *Invest Ophthalmol Vis Sci* 2011;52:3354-59.
281. Gangaputra S, Almkhatar T, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Diabetic Retinopathy Clinical Research Network. Comparison of film and digital fundus photographs in eyes of individuals with diabetes mellitus. *Invest Ophthalmol Vis Sci* 2011;52:6168-73.
282. Lopes MS, Zayit-Soudry S, Moshiri A, Bressler SB, Bressler NM. Understanding and reporting visual acuity measurements in publications of clinical research. *Arch Ophthalmol* 2011;129:1228-29.
283. Lauer AK, Bressler NM, Edwards AR; Diabetic Retinopathy Clinical Research Network. Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network. *Arch Ophthalmol* 2011;129:1097-99.
284. Bressler NM, Beck RW, Ferris FL. Panretinal photocoagulation for proliferative diabetic retinopathy. *N Engl J Med* 2011;365:1520-26.
285. Wenick AS, Bressler NM. Diabetic macular edema: current and emerging therapies. *Middle East Afr J of Ophthalmol* 2012;19:4-12.
286. Kowalski JW, Rentz AM, Walt JG, Lloyd, A, Lee J, Young TA, Chen W, Bressler NM, Lee P, Brazier JE, Hays RD, Revicki DA. Rasch analysis in the development of a simplified version of the National Eye Institute Visual-Function Questionnaire-25 for utility estimation. *Qual Life Res* 2012;21:323–34.
287. Sun JK, Qin H, Aiello LP, Melia M, Beck RW, Andreoli CM, Edwards PA, Glassman AR, Pavlica MR; Diabetic Retinopathy Clinical Research Network. Evaluation of visual acuity measurements after autorefraction vs manual refraction in eyes with and without diabetic macular edema. *Arch Ophthalmol* 2012;130:470-79.
288. Do DV, Gower EW, Cassard SD, Boyer D, Bressler NM, Bressler SB, Heier JS, Jefferys JL, Singerman LJ, Solomon SD. Detection of new on-set choroidal neovascularization using optical coherence tomography: The AMD DOC Study. *Ophthalmology* 2012;119:771-78.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

289. Shah AM, Bressler NM, Jampol LM. Does laser still have a role in the management of retinal vascular and neovascular diseases? *Am J Ophthalmol* 2011;152:332-39.
290. Glassman AR, Stockdale CR, Beck RW, Baker C, Bressler NM; Diabetic Retinopathy Clinical Research Network. Evaluation of masking study participants to intravitreal injections in a randomized clinical trial. *Arch Ophthalmol* 2012;130:190-94.
291. Campbell JP, Bressler S, Bressler N. Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration. *Arch Ophthalmol* 2012;130:794-95.
292. Bhavsar AR, Stockdale CR, Ferris FL 3<sup>rd</sup>, Brucker AJ, Bressler NM, Glassman AR; Diabetic Retinopathy Clinical Research Network. Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics. *Arch Ophthalmol* 2012;130:809-10.
293. Bressler NM, Miller KM, Beck RW, Bressler SB, Glassman AR, Kitchens JW, Melia M, Schlossman DK for the Diabetic Retinopathy Clinical Research Network. Observational study of subclinical diabetic macular edema. *Eye* 2012;26:833-40.
294. Casparis H, Lindsley K, Kuo IC, Sikder S, Bressler NM. Surgery for cataracts in people with age-related macular degeneration. *Cochrane Database of Syst Rev* 2012; 6: CD006757.
295. Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, Ferris FL, Glassman AR, Maturi RK, Melia M, for the Diabetic Retinopathy Clinical Research Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. *Ophthalmology* 2012;119:2312–18.
296. Bressler NM, Boyer DS, Williams DF, Butler S, Francom SF, Brown B, Di Nucci F, Cramm T, Tuomi LL, Ianchulev T, Rubio RG. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. *Retina* 2012;32:1821-28.
297. Bressler NM, Chang TS, Varma R, Suñer I, Lee P, Dolan C, Ward J, Ianchulev T, Fine J. Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab. *Ophthalmology* 2013;120:160-68.
298. Bressler NM, Beck RW, Ferris FL. In reply to Letters to Editor. *N Engl J Med* 2012; 366:277-79.
299. Varma R, Bressler N, Suñer I, Lee P, Dolan C, Ward J, Colman S, Rubio R, BRAVO and CRUISE Study Groups. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. *Ophthalmology* 2012;119:2108-18.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

300. Orr P, Rentz AM, Margolis MK, Revicki DA, Dolan CM, Colman S, Fine JT, Bressler NM. Author response: Validation of the National Eye Institute Visual Function Questionnaire-25 (NEIVFQ-25) in age-related macular degeneration. *Invest Ophthalmol Vis Sci* 2012;53:7950.
301. Diabetic Retinopathy Clinical Research Network, Bressler NM, Miller KM, Beck RW, Bressler SB, Glassman AR, Kitchens JW, Melia M, Schlossman DK. Observational study of subclinical diabetic macular edema. *Eye* 2012;26:900-01.
302. Chalam KV, Bressler SB, Edwards AR, Berger BB, Bressler NM, Glassman AR, Grover S, Gupta SK, Nielsen JS; Diabetic Retinopathy Clinical Research Network. Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg Spectralis optical coherence tomography. *Invest Ophthalmol Vis Sci* 2012;53:8154-61.
303. Kankanahalli S, Burlina PM, Wolfson Y, Freund DE, Bressler NM. Automated classification of severity of age-related macular degeneration from fundus photographs. *Invest Ophthalmol Vis Sci* 2013;54:1789-96.
304. Mitchell P, Bressler NM, Tolley K, Gallagher M, Petrillo J, Ferreira A, Wood R, Bandello F. Patient-reported visual function outcomes improve following ranibizumab treatment in patients with vision impairment due to diabetic macular edema. *JAMA Ophthalmol* 2013;131:1339-47.
305. Suñer I, Bressler NM, Varma R, Lee P, Dolan CM, Ward J, Colman S, Rubio RG. Reading speed improvements in retinal vein occlusion following ranibizumab treatment. *JAMA Ophthalmol* 2013;131:851-56.
306. Chaikitmongkol V, Bressler NM. Dramatic resolution of choroidal neovascular abnormalities after single aflibercept injection following years of ranibizumab use. *JAMA Ophthalmol* 2013;131:260-62.
307. Diabetic Retinopathy Clinical Research Network. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. *JAMA Ophthalmol* 2013;131:283-93.
308. Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, Grover S, Miller DG, for the Diabetic Retinopathy Clinical Research Network. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. *JAMA Ophthalmol* 2013;131:1033-40.
309. Trucco E, Ruggeri A, Karnowski T, Giancardo L, Chaum E, Hubschman JP, al-Diri B, Cheung CY, Wong D, Abramoff M, Lim G, Kumar D, Burlina P, Bressler NM, Jelinek HF, Meriaudeau F, Quellec G, Macgillivray T, Dhillon B. Validating retinal fundus image analysis algorithms: issues and a proposal. *Invest Ophthalmol Vis Sci* 2013;54:3546-59.



**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

310. Bressler SB, Almkhatar T, Aiello LP, Bressler NM, Ferris FL 3<sup>rd</sup>, Glassman AR, Greven CM; Diabetic Retinopathy Clinical Research Network. Green or yellow laser treatment for diabetic macular edema: exploratory assessment within the Diabetic Retinopathy Clinical Research Network. *Retina* 2013;10:2080-88.
311. Diabetic Retinopathy Clinical Research Network Authors/Writing Committee, Bressler SB, Baker CW, Almkhatar T, Bressler NM, Edwards P, Glassman AR, Scott MH. Pilot study of individuals with diabetic macular edema undergoing cataract surgery. *JAMA Ophthalmol* 2014;132:224-26.
312. Bressler NM. *JAMA Ophthalmology*: it's not just a new name. *JAMA Ophthalmol* 2013;131:839.
313. Sünner IJ, Bressler NM, Varma R, Lee P, Dolan CM, Ward J, Colman S, Rubio RG. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. *JAMA Ophthalmol* 2013;131:851-56.
314. Diabetic Retinopathy Clinical Research Network Authors/Writing Committee, Bressler NM, Glassman AR, Grover S, Kim SJ, Murtha TJ, Rauser ME, Stockdale C, Baker CW, Almkhatar T. Macular edema after cataract surgery in eyes without preoperative central-involved diabetic macular edema. *JAMA Ophthalmol* 2013;131:870-79.
315. Mitchell P, Bressler NM, Tolley K, Gallagher M, Petrillo J, Ferreira A, Wood R, Bandello F; RESTORE Study Group. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: Randomized clinical trial. *JAMA Ophthalmol* 2013;131:1339-47.
316. Rentz AM, Kowalski JW, Walt JG, Hays RD, Brazier JE, Yu R, Lee P, Bressler NM, Revicki DA. Development of a preference-based index from the National Eye Institute Visual Function Questionnaire-25. *JAMA Ophthalmol* 2014;132:310-18.
317. Bressler NM, Varma R, Doan QV. Vulnerable populations in the underuse of the US health care system by persons with diabetes mellitus and diabetic macular edema-reply. *JAMA Ophthalmol* 2014;132:1030-31.
318. Bressler NM, Varma R, Doan QV, Gleeson M, Danese M, Bower JK, Selvin E, Dolan C, Fine J, Colman S, Turpcu A. Underuse of the healthcare system by persons with diabetic macular edema in the United States. *JAMA Ophthalmol* 2014;132:168-173.
319. Bressler NM, Beck RW, Kass MA. *JAMA Ophthalmology* publication policies and procedures fresh start for a new year. *JAMA Ophthalmol* 2014;132:11-12.
320. Bressler NM, Bressler SB, Liu MM, Wolfson Y, Do DV, Ying HS. Comparison of time and spectral domain optical coherence tomography in management of diabetic macular edema. *Invest Ophthalmol Vis Sci* 2014;55:1370-77.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

321. Jampol LM, Bressler NM, Glassman AR. Revolution to a new standard treatment of diabetic macular edema. *JAMA* 2014;311:2269-70.
322. Bhavsar AR, Torres K, Bressler NM, Glassman AR, Jampol LM, Kinyoun JL. Evaluation of results one year following short-term use of ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy. *JAMA Ophthalmol* 2014;132:889-90.
323. Mitchell P, Bressler NM, Doan QV, Dolan C, Ferreira A, Osborne A, Rochtchina E, Danese M, Colman S, Wong TY. Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment. *PLoS One* 2014;9:e101072.
324. Chaikitmongkol V, Bressler NM, Bressler SB. Early detection of choroidal neovascularization facilitated with a home monitoring program in age-related macular degeneration. *Retin Cases Brief Rep* 2014; 9:33-37.
325. Chaikitmongkol V, Bressler NM. Intraretinal fibrosis in exudative diabetic macular edema after ranibizumab treatments. *Retin Cases Brief Rep* 2014;8:336-39.
326. Do DV, Bressler SB, Cassard SD, Gower EW, Tabandeh H, Jeffreys JL, Bressler NM. Ranibizumab for macular telangiectasia type 2 in the absence of subretinal neovascularization. *Retina* 2014;34:2063-71.
327. Paulus YM, Bressler NM. Spontaneous improvement in myopic foveoschisis. *Eye* 2014;28:1519-20.
328. Bressler NM, Varma R, Suñer IJ, Dolan CM, Ward J, Ehrlich JS, Colman S, Turpcu A; RIDE and RISE Research Groups. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. *Ophthalmology* 2014;121:2461-72.
329. Varma R, Bressler NM, Doan QV, Danese M, Dolan CM, Lee A, Turpcu A. Visual impairment and blindness avoided with ranibizumab in Hispanic and non-Hispanic whites with diabetic macular edema in the United States. *Ophthalmology* 2015; 122:982-9.
330. Friedman SM, Almukhtar TH, Baker CW, Glassman AR, Elman MJ, Bressler NM, Maker MP, Jampol LM, Melia M; Diabetic Retinopathy Clinical Research Network. Topical nepafenac in eyes with non-central diabetic macular edema. *Retina* 2015; 35: 944-956.
331. Elman MJ, Bressler NM, Ayalaya LP, Browning D, Flexel CJ, Glassman AR, Jampol LM, Stone TW. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. *Ophthalmology* 2015;122:378-81.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

332. Bressler SB, Edwards AR, Chalam KV, Bressler NM, Glassman AR, Jaffe GJ, Melia M, Saggau DD, Plous OZ. Reproducibility of spectral-domain optical coherence tomography retinal thickness measurements and conversion to equivalent time-domain metrics in diabetic macular edema. *JAMA Ophthalmol* 2014;132:1113-122.
333. Varma R, Bressler NM, Doan QV, Gleeson M, Danese M, Bower JK, Selvin E, Dolan C, Fine J, Colman S, Turpcu A. Prevalence of and risk factors for diabetic macular edema in the United States. *JAMA Ophthalmol* 2014;132:1334-40.
334. Tanaka E, Chaikitmongkol V, Bressler SB, Bressler NM. Vision-threatening lesions developing with longer-term follow-up after treatment of neovascular age-related macular degeneration. *Ophthalmology* 2015;122:153-61.
335. Bressler NM, Bauchner H. Expression of Concern: Thankur A, Kadam R, Kompella UB. Trabecular meshwork and lens partitioning of corticosteroids. *JAMA Ophthalmol* 2015;133.
336. Varma R, Bressler NM, Doan QV, Danese M, Dolan CM, Lee A, Turpcu A. Visual impairment and blindness avoided with ranibizumab in Hispanic and Non-Hispanic Whites with diabetic macular edema in the United States. *Ophthalmology* 2015;122:982-989.
337. Jampol LM, Glassman AR, Bressler NM. Comparative effectiveness trial for diabetic macular edema: Three comparisons for the price of one study. *JAMA Ophthalmol* 2015;133:983-984.
338. Friedman SM, Almkhatar TH, Baker CW, Glassman AR, Elman MJ, Bressler NM, Maker MP, Jampol LM, Melia M, Diabetic Retinopathy Clinical Research Network. Topical nepafenec in eyes with non-central diabetic macular edema. 2015;35:944-56.
339. Elman MJ, Ayala A, Bressler NM, Browning D, Flaxel CJ, Glassman AR, Jampol LM, Stone TW, for the Diabetic Retinopathy Clinical Research Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5 year-randomized trial results. *Ophthalmology* 2015;122:375-381.
340. Wang YT, Bressler NM. Treatment of proliferative diabetic retinopathy with intravitreal injection of ranibizumab. *AMSRJ* 2015;2:150-154.
341. Han IC, Singerman LJ, Schmaier A, Bressler NM. Bilateral, multiple, episodic retinal vein occlusions associated with common variable immunodeficiency. *JAMA Ophthalmol* 2015;133:1216-1218.
342. Bressler SB, Melia M, Glassman AR, Almkhatar T, Jampol LM, Shami, M, Berger BB, Bressler NM. Ranibizumab plus prompt or deferred laser for diabetic macular edema in eyes with vitrectomy before anti-vascular endothelial growth factor therapy. *Retina* 2015;35:2516-2528.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

343. Mitchell P, Massin P, Bressler S, Coon C, Petrillo J, Ferreira A, Bressler N. Three-year patient-reported visual function outcomes in diabetic macular edema managed with ranibizumab: the RESTORE extension study. *Curr Med Res Opin* 2015;31:1967-1975.
344. Thomas M, Wolfson Y, Zayit-Soudry S, Bressler SB, Bressler NM. Qualifying to use a home device to monitor for detection of neovascular age-related macular degeneration. *JAMA Ophthalmol*. 2015;133:1425-1430.
345. Feeny AK, Tadarati M, Freund DE, Bressler NM, Burlina P. Automated segmentation of geographic atrophy of the retinal epithelium via random forests in AREDS color fundus images. *Comput Biol Med* 2015;65:124-136.
346. Aiello LP, Ayala AR, Antoszyk AN, Arnold-Bush B, Baker C, Bressler NM, Elman MJ, Glassman AR, Jampol LM, Melia M, Nielsen J, Wolpert HA; Diabetic Retinopathy Clinical Research Network. Assessing the effect of personalized diabetes risk assessments during ophthalmologic visits in glycemic control: a randomized clinical trial. *JAMA Ophthalmol* 2015;133:888-896.
347. Bressler SB, Almkhatar T, Bhorade A, Bressler NM, Glassman AR, Huang SS, Jampol LM, Kim JE, Melia M, Diabetic Retinopathy Clinical Research Network Investigators. Repeated intravitreal ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. *JAMA Ophthalmol* 2015;133:589-597.
348. Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, for diabetic macular edema. *N Engl J Med*. 2015; 372:1193-203.
349. Bressler SB, Melia M, Glassman AR, Almkhatar T, Jampol LM, Shami M, Berger BB, Bressler NM, ; for the Diabetic Retinopathy Clinical Research Network. Ranibizumab plus prompt or deferred laser for diabetic macular edema in eyes with vitrectomy before anti-vascular endothelial growth factor therapy. *Retina* 2015;35:2516-2528, 2015.349.
350. Diabetic Retinopathy Clinical Research Network Writing Committee. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. *N Engl J Med* 2015;372:1193-203.
351. Bressler NM, Varma R, Mitchell P, Suñer IJ, Dolan C, Ward J, Ferreira A, Ehrlich JS, Turpcu A. Impact of ranibizumab on decision to drive and vision function relevant to driving in patients with diabetic macular edema: report from RESTORE, RIDE, and RISE Trials. *JAMA Ophthalmol* 2016;134:160-166.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

352. Wang YT, Tadarati M, Scholl HP, Bressler NM. Recurrence of vitelliform lesions associated with temporary vision loss in best vitelliform macular dystrophy. *Retin Cases Brief Rep* 2016;10:63-71.
353. Heier JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, Brown DM, Dugel PU, Freund B, Glassman AR, Kim JE, Martin DF, Pollack JS, Regillo C, Rosenfeld PJ, Schachat AP, Wells JA, for the American Society of Retina Specialists anti-VEGF to diabetic macular edema comparative effectiveness panel. Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: Extrapolation of data to clinical practice. *JAMA Ophthalmol* 2016;134:95-99.
354. Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation vs intravitreal ranibizumab for proliferative diabetic retinopathy. A randomized clinical trial. *JAMA* 2015;314:2137-2146.
355. Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW, Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-year Results from a Comparative Effectiveness Randomized Clinical Trial. *Ophthalmology*. 2016;123:1351-1359.
356. Chaikitmongkol V, Tadarati M, Bressler NM. Recent approaches to evaluation and monitoring geographic atrophy. *Curr Opin Ophthalmol* 2016;27:217-223.
357. Wang YT, Tadarati M, Wolfson Y, Bressler SB, Bressler NM. Comparison of prevalence of diabetic macular edema based on monocular fundus photography vs optical coherence tomography. *JAMA Ophthalmol* 2016;134:222-228.
358. Beaulieu WT, Bressler NM, Melia M, Owsley C, Mein CE, Gross JG, Jampol LM, Glassman, AR, for the Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation versus ranibizumab for proliferative diabetic retinopathy; patient-centered outcomes from a randomized clinical trial. *Am J Ophthalmol* 2016;170:206-213.
359. Burlina P, Freund DE, Joshi N, Wolfson JY, Bressler NM. Detection of age-related macular degeneration via deep learning. *Proc IEEE Int Symp Biomed Imaging* 2016;184-188.
360. Bhavsar AR, Glassman AR, Stockdale CR, Jampol LM, for the Diabetic Retinopathy Clinical Research Network. Elimination of topical antibiotics for intravitreal injections and the importance of using povidone-iodine Update from the Diabetic Retinopathy Clinical Research Network. *JAMA Ophthalmol* 2016;134:1181-1183.
361. Scott AW, Bressler NM, Folkes SF, Wittenborn JS, Jorkasky J. Public attitudes about eye and vision health. *JAMA Ophthalmol*. 2016;134:1111-1118.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

362. Bressler SB, Glassman A, Almkhatar T, Bressler NM, Ferris FL, Googe JM, Gupta SK, Jampol LM, Melia M, Wells JA. Diabetic Retinopathy Clinical Research Network. Five year outcomes of ranibizumab with prompt or deferred laser versus laser or triamcinolone plus deferred ranibizumab for diabetic macular edema. *Am J Ophthalmol.* 2016;164:57-68.
363. Bressler SB, Ayala AR, Bressler NM, Melia M, Qin H, Ferris FL, Flaxel CJ, Friedman SM, Glassman AR, Jampol LM, Rauser ME. Diabetic Retinopathy Clinical Research. Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. *JAMA Ophthalmol.*2016;134:278-285.
364. Wong TY, Bressler NM. Artificial intelligence with deep learning technology looks into diabetic retinopathy screening. *JAMA* 2016;316:2366-2367.
365. Jampol LM, Glassman AR, Bressler NM, Wells JA, Ayala AR for the Diabetic Retinopathy Clinical Research Network. Anti-vascular endothelial growth factor comparative effectiveness trail for diabetic macular edema additional efficacy post hoc analyses of a randomized clinical trial. *JAMA Ophthalmol.* 2016;134:1429-1434.
366. Suñer IJ, Bressler NM, Varma R, Dolan CM, Ward J, Turpcu A. Responsiveness of the National Eye Institute visual function questionnaire-25 to visual acuity gains in patients with diabetic macular edema: evidence from the RIDE and RISE trials. *Retina* 2017;37:1126-1133.
367. Bressler NM. *JAMA Ophthalmology* Year in Review, 2016. *JAMA Ophthalmol.* 2017;135:187-188.
368. Casparis H, Lindsley K, Kuo IC, Sikder S, Bressler NM. Surgery for cataracts in people with age-related macular degeneration (Review). *Cochrane database of systematic reviews* 2017, Issue 2. Art. No:CD006757.
369. Gottlieb JD, Bressler NM. How should journals handle the conflict of interest in their editors: Who watches the “watchers”? *JAMA* 2017;17:1757-1758.
370. Le, JT, Hutfless, S, Li, T, Bressler, NM, Heyward, J, Bittner, AK, Glassman, A, Dickersin, K. Setting priorities for diabetic retinopathy clinical research and identifying evidence gaps. *Ophthalmol Retina* 2017;1:94-102.
371. Beaulieu, WT, Bressler, NM, Gross, JG, for the Diabetic Retinopathy Clinical Research Network. Correspondence: Panretinal photocoagulation versus ranibizumab for proliferative retinopathy: Patient-centered outcomes from a randomized clinical trial. *Am J Ophthalmol* 2017;177:233.
372. Tsou, BC, Bressler, NM. Visual acuity reporting in clinical research publications. *JAMA Ophthalmol* 2017;135:651-653.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

373. Gross, JG, Glassman, AR, Klein, MJ, Jampol, LM, Ferris, FL, Bressler, NM, Beck, RW. Research letter: Interim safety data comparing ranibizumab with panretinal photocoagulation among participants with proliferative diabetic retinopathy. *JAMA Ophthalmol* 2017;135:672-673.
374. Hariri, AH, Velaga SB, Girach A, Ip MS, Le PV, Lam BL, Fischer MD, Sankila EM, Pennesi M, Holz FG, MacLaren RE, Birch DG, Hoyng CB, MacDonald IM, Black GC, Tsang, SH, Bressler, NM, Larsen, M, Gorin, MB, Webster, AR, Sadda R, for natural history of the progression of choroideremia (NIGHT) Study Group. Measurement and reproducibility of preserve ellipsoid zone area and preserved RPE area in a cohort of eyes with choroideremia. *Am J Ophthalmol* 2017;179:110-117.
375. Bressler NM. Treatment of macular edema due to central retinal vein occlusion: another score for repackaged bevacizumab. *JAMA* 2017;317:2067-2069.
376. Scott, IU, and other coauthors for the SCORE2 Investigators Group. Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: The SCORE2 Randomized Clinical Trial. *JAMA*. 2017;135:2072-2087.
377. Suñer , IJ, Bressler, NM, Varma, R, Dolan, CM, Ward, J, Turpcu, A. Responsiveness of the National Eye Institute visual function questionnaire-25 to visual acuity gains in patients with diabetic macular edema Evidence from the RIDE and RISE Trials. *Retina* 2017;37:1126-1133.
378. Hutton DW, Stein JD, Bressler NM, et al. Cost-effectiveness of intravitreal ranibizumab compared with panretinal photocoagulation for proliferative diabetic retinopathy: secondary analysis from a Diabetic Retinopathy Clinical Research Network randomized clinical trial. *JAMA Ophthalmol* 2017;135:576–584.
379. Petrillo, J, Bressler, NM, Lamoureux, E, Ferreira, A, Cano, S. Development of a new Rasch-based scoring algorithm for the National Eye Institute Visual Functioning Questionnaire to improve its interpretability. *Health Qual Life Outcomes* 2017;15:15:157.
380. Arevalo, JF, Kong, J, Bressler, NM. Safely viewing solar eclipses. *JAMA* 2017;318:1080.
381. Bressler NM, Chan CKM, Wong IY, Brelen M, Chan W, Ho C, Liu D, Lai TYY. Optimizing management of diabetic macular edema in Hong Kong: a collaborative position paper. *Hong Kong J Ophthalmol* 2017;21:59-64.
382. Burlina PM, Joshi N, Pekala M, Pacheco KD, Freund DE, Bressler NM. Automated grading of age-related macular degeneration from color fundus images using deep convolutional neural networks. *JAMA Ophthalmol* 2017;135:1170-1176.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

383. Bauchner H, Rivera F, Bonow R, Bressler N, Disis N, Josephson A, Heckers S, Kibbe M, Piccirillo J, Redberg R, Rhee J, Robinson J. The epidemic of guns: a public health crisis. *JAMA Ophthalmol* 2017;135:1293-1294.
384. Cai S, Bressler NM. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T. *Curr Opin Ophthalmol* 2017;28:636-643.
385. Krick, TW, Bressler, NM, Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network. *Curr Opin Ophthalmol* 2018;29:199-205.
386. Bressler NM. *JAMA Ophthalmology*—the year in review, 2017: *JAMA Ophthalmology* looks forward to continued globalization in 2018. *JAMA Ophthalmol* 2018;136:465-466.
387. Maturi RK, Glassman AR, Liu D, Beck RW, Bhavsar AR, Bressler NM, et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR Network phase 2 randomized clinical trial. *JAMA Ophthalmol* 2018;136:29–38.
388. Chaikitmongkol, V, Upaphong, P, Patikulasila, D, Bressler, NM. OCT vs. ICG angiography features of polypoidal choroidal vasculopathy. *Ophthalmol Retina* 2018;2:170-172.
389. Sivaprasad S, Tschosik E, Kapre A, Varma R, Bressler NM, Kimel M, Dolan C, Silverman D. Reliability and construct validity of the NEI VFQ-25 in a subset of patients with geographic atrophy from the phase 2 Mahalo study. *Am J Ophthalmol* 2018;190:1-8.
390. Holz FG, Sadda SR, Busbee B, et al. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri phase 3 randomized clinical trials. *JAMA Ophthalmol* 2018;136:666–677.
391. Bressler NM, Beaulieu WT, Glassman AR, et al. Persistent macular thickening following intravitreal aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. *JAMA Ophthalmol* 2018;136:257–269.
392. Jampol LM, Glassman AR, Liu D, Aiello LP, Bressler NM, Duh EJ, Quaggin S, Wells JA, Wykoff CC for the Diabetic Retinopathy Clinical Research Network. Plasma vascular endothelial growth factor concentrations after intravitreal anti-vascular endothelial growth factor. *Ophthalmology* 2018;125:1054-1063.
393. Pekala M, Joshi N, Freund DE, Bressler NM, DeBuc DC, Burlina PM. Deep learning based retinal OCT segmentation. 2018;arXiv preprint arXiv:1801.09749.



**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

394. Linz MO, Bressler NM, Chaikitmongkol V, Sivaprasad S, Patikulsila D, Choovuthayakorn J, Watanachai N, Kuavisarut P, Menon D, Tadarati M, Pacheco KD, Sanyal A, Scott AW. Vision preference value scale and patient preferences in choosing therapy for symptomatic vitreomacular interface abnormality. *JAMA Ophthalmol* 2018; 136:658-664.
395. Gross JG, Glassman AR, Liu D, Sun JK, Antoszyk AN, Baker CW, Bressler NM, Elman MJ, Ferris FL, Gardner TW, Jampol LM, Martin DF, Melia M, Stockdale R, Beck RW for the Diabetic Retinopathy Clinical Research Network. Five-year outcomes of panretinal photocoagulation vs intravitreal ranibizumab for proliferative diabetic retinopathy a randomized clinical trial. *JAMA Ophthalmol* 2018;136:1138-1148.
396. Chaikitmongkol V, Khunsongkiet P, Patikulsila D, Ratanasukon M, Watanachai N, Jumroendarasmae C, Meyerle CB, Han IC, Chen CJ, Winaikosol P, Dejkriengkraikul C, Choovuthayakorn J, Kunavisarut P, Bressler NM. Color fundus photography, optical coherence tomography, and fluorescein angiography in diagnosing polypoidal choroidal vasculopathy. *Am J Ophthalmol* 2018;192:77-83.
397. Burlina P, Joshi N, Pacheco K, Freund DE, Kong J, Bressler NM. Utility of deep learning methods for referability classification of age-related macular degeneration. *JAMA Ophthalmol* 2018;136:1305-1307.
398. Hariri AH, Ip MS, Girach A, Lam BL, Fischer MD, Sankil E, Pennesi ME, Holz FG, MacLaren RE, Birch D, Hoyng CB, MacDonald IM, Black GC, Tsang SH, Bressler NM, Stepien KE, Larsen M, Gorin MB, Meunier I, Webster AR, Sadda S. Macular spatial distribution of preserved autofluorescence in patients with choroideremia. *Br J Ophthalmol* 2018; on line October 8, 2018.
399. Chaikitmongkol V, Nanegrungsunk O, Patikulsila D, Ruamviboonsuk P, Bressler NM. Repeatability and agreement of visual acuity using the ETDRS number chart, Landolt C chart, or ETDRS alphabet chart in eyes with or without sight-threatening diseases. *JAMA Ophthalmol* 2018;136:286–290.
400. Varma R, Souied ER, Tufail A, Tschosik E, Ferrara D, Zhang J, Silverman D, Dolan C, Bressler NM. Maximum reading speed in patients with geographic atrophy secondary to age-related macular degeneration. *Invest Ophthalmol Vis Sci* 2018;59:AMD195-AMD201.
401. Pieramici DJ, Holz F, Heier JS, Sadda SR, Busbee BG, Chew EY, Mitchell P, Tufail A, Brittain C, Ferrara D, Gray S, Honigberg L, Martin J, Tong B, Ehrlich J, Bressler NM. Lampalizumab for geographic atrophy (GA) in age-related macular degeneration (AMD): pooled results of the Chroma and Spectri phase 3 randomized clinical trials (RCTs). *Invest Ophthalmol Vis Sci* 2018;59:4948-4948.
402. Chaikitmongkol V, Nanegrungsunk O, Patikulsila D, Choovuthayakorn J, Watanachai N, Kunavisarut P, Ittipunkul N, Bressler NM. Post-injection endophthalmitis

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – December 28, 2018

in eyes receiving vs. not receiving topical antibiotic prophylaxis in Northern Thailand. *Eye* 2018;32:1911–1913.

403. Bressler NM, Beaulieu WT, Maguire MG, Glassman AR, Blinder KJ, Bressler SB, Gonzalez VH, Jampol LM, Melia M, Sun JK, Wells JA for the Diabetic Retinopathy Clinical Research Network. Early response to anti-vascular endothelial growth factor and two-year outcomes among eyes with diabetic macular edema in protocol T. *Am J Ophthalmol* 2018;195:93-100.
404. AI for medical imaging goes deep. *Nat Med* 2018;24:539.
405. PM Burlina, N Joshi, KD Pacheco, DE Freund, J Kong, NM Bressler. Use of deep learning for detailed severity characterization and estimation of 5-year risk among patients with age-related macular degeneration. *JAMA Ophthalmol* 2018;136:1359-1366.
406. Bressler, NM. Deep generative models for high-resolution synthetic retinal image generation with relevance to humans and machines. In press *JAMA Ophthalmol* 2019;137: in press January 10, 2019.
407. Jampol LM, Odia I, Glassman AR, Baker CW, Bhorade AM, Han DP, Jaffe GJ, Melia M, Bressler NM, Tanna AP, for Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation versus ranibizumab for proliferative diabetic retinopathy: comparison of peripapillary retinal nerve fiber layer thickness in a randomized clinical trial. *Retina* 2019;39:69-78.
408. Sun JK, Glassman AR, Beaulieu WT, Stockdale CR, Bressler NM, Flaxel C, Gross JG, Shami M, Jampol LM for the Diabetic Retinopathy Clinical Research Network. Rationale and application of the protocol S anti-vascular endothelial growth factor algorithm for proliferative diabetic retinopathy. *Ophthalmology* 2019;126:87-95.
409. Aiello LP, Odia I, Glassman AR, Melia M, Jampol L, Bressler NM, et al. Comparison of Early Treatment Diabetic Retinopathy Study standard 7-field imaging with ultrawide-field imaging for determining severity of diabetic retinopathy. *JAMA Ophthalmol* 2018; published online October 18, 2018.

---

## TEXTBOOKS

Bressler NM, Brown GC, Flynn HW, Marmor MF, Anderson LS, Grand MG. American Academy of Ophthalmology's Basic Clinical Skills Course Section 12: Retina and Vitreous, 1996-1997, 1996.

**BOOK CHAPTERS**

1. Bressler NM, Bressler SB, Berson FG: Ophthalmic agents. In Manual of Drug Therapy. Eds. Steinberg DA, Scheinberg LC. New York: Raven Press, 1985.
2. Bressler SB, Bressler NM, Murphy RP: Argon laser treatment: randomized clinical trials--short and long term results. In Ocular Circulation and Neovascularization. Eds BenEzra D, Ryan SJ. Boston: Martinus Nijhoff Publishers, 1987.
3. Bressler NM, Bressler SB, Murphy RP, Fine SL: Recurrent choroidal neovascularization following successful photocoagulation in age-related macular degeneration. In Ocular Circulation and Neovascularization. Eds BenEzra D, Ryan SJ. Boston: Martinus Nijhoff Publishers, 1987.
4. Bressler NM, Bressler SB, Murphy RP, Fine SL: Recurrent choroidal neovascularization following successful photocoagulation in age-related macular degeneration. In Laser Photocoagulation of Retinal Disease. Eds Gitter KA, Schatz H, Yannuzzi LA, McDonald HR. San Francisco: Pacific Medical Press, 1988.
5. Bressler NM, Bressler SB: Laser treatment in macular degeneration and histoplasmosis. In Ophthalmology Clinics of North America: Practical Laser Surgery and Its New Frontiers. Ed March WF. Philadelphia: WB Saunders Co, 1989.
6. Bressler SB, Bressler NM: Traumatic maculopathy. In Ocular Trauma. Eds, Hersh P, Shingleton B, Topping T, 1991.
7. Bressler NM, Bressler SB, Fine SL: Angiographic interpretation of classic and occult choroidal neovascularization. In Medical and Surgical Retina: Advances, Controversies and Management. Eds Lewis H, Ryan S. St. Louis: Mosby Year Book, 1992.
8. Bressler NM: Macular degeneration and related disorders. In Practical Atlas of Retinal Disease and Therapy. Ed. Freeman WR. New York: Raven Press, 1992.
9. Bressler SB, Gragoudas ES, Bressler NM: Age related macular degeneration, Part 1: Drusen and Geographic Atrophy. In Principles and Practice of Ophthalmology. Eds Albert DM, Jakobiec FA, WB Saunders Co, 1993.
10. Bressler NM, Gragoudas ES, Bressler SB: Age related macular degeneration, Part 2: RPE Detachment and Subretinal neovascularization. In Principles and Practice of Ophthalmology. Eds Albert DM, Jakobiec FA, WB Saunders Co, 1993.
11. Bressler SB, Bressler NM, Fine SL: Photocoagulation of choroidal neovascularization. In Medical and Surgical Retina: Advances, Controversies and Management. Eds Lewis H, Ryan S. St Louis: Mosby Year Book, 1994.

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – November 1, 2018

12. Bressler NM: Laser management of choroidal neovascularization. Focal Points Module, American Academy of Ophthalmology, 1993.
13. Neely KA, Bressler NM, Bressler SB: Epidemiology, clinical characteristics, and natural history of age-related macular degeneration. In Ophthalmology Clinics of North America: Macular Diseases. Eds., Grossniklaus HE, Kincaid MC. WB Saunders Co, 1993.
14. Bressler NM: Subretinal neovascular membrane. Master Techniques in Ophthalmic Surgery. Ed., Roy FH. Williams and Wilkins, 1995.
15. Bressler NM: Macular degeneration and related disorders. In Practical Atlas of Retinal Disease and Therapy 2nd edition. Ed. Freeman WR. New York: Raven Press, 1997.
16. Fekrat S, Bressler NM: Age Related Maculopathy. Easty and Sparrow: Oxford Textbook of Ophthalmology, Oxford University Press 1999.
17. Rosberger DF, Bressler NM, Bressler SB: Ophthalmic Surgery: Photocoagulation. Rob & Smith's Operative Surgery, Eds., Carter DC, Russell RCG, Pitt HA, Dudley H, Lee G, Remes P, Stockman L, Ramage D. Chapman & Hall, 1998.
18. Loewenstein A, Bressler NM: Macular Photocoagulation Study. Retina, Vitreous, Macula: A Comprehensive Text, Eds., Guyer DR, Yannuzzi LA, Chang S, Shields J, Green WR. Saunders Publishing Company, Philadelphia, PA, 1998.
19. Bressler NM, Edwards M: Age-related macular degeneration. In Ophthalmology, section 8: Retinal and Vitreous. Ed. Duker J. Mosby-Wolfe Publishing, London, 1998.
20. Loewenstein A, Bressler NM, Bressler SB. Epidemiology of RPE disease. In Retinal Pigment Epithelium: Current Aspects of Function and Disease. Eds. Marmor MF, Wolfensberger TJ. New York: Oxford University Press, 1999.
21. O'Connell SR, Bressler NM: Age-related macular degeneration. In The Essentials of VitreoRetinal Disease, 1st edition. Ed. Brown GC, Flynn HW, Regillo CD. New York, Thieme Medical Publishing, 1998.
22. Bressler SB, Gragoudas ES, Bressler NM: Age-related macular degeneration, Part 1: Drusen and Geographic Atrophy. In Principles and Practice of Ophthalmology, 2nd Edition. Eds Albert DM, Jakobiec FA, WB Saunders Co, 1999.
23. Bressler NM, Gragoudas ES, Bressler SB: Age-related macular degeneration, Part 2: RPE Detachment and Subretinal neovascularization. In Principles and Practice of Ophthalmology, 2nd Edition. Eds Albert DM, Jakobiec FA, WB Saunders Co, 1999.
24. Bressler NM, Bressler SB, Fine SL: Neovascular (exudative) age-related macular degeneration. In Medical and Surgical Retina: Advances, Controversies and

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – November 1, 2018

Management (Third Edition). Eds Ryan S, Schachat AP. St Louis: Mosby Year Book, 2000.

25. Weisz JM, Bressler NM, Bressler SB: Choroidal neovascularization: Laser treatment. In Macular Surgery. Eds Quiroz-Mercado H, Liggett P, Alfaro V, de Juan E, Tano Y. Lippincott, Williams & Wilkins, July 2000.
26. Do DV, Bressler SB, Bressler NB: Pathologic myopia and choroidal neovascularization. In Myopia. Eds. B.G. Bietti Foundation's Sixth International Congress. 2004.

---

**FEDERALLY-SUPPORTED (National Institutes of Health) RESEARCH GRANTS**

*CURRENTLY ACTIVE NIH SUPPORT:*

*COMPLETED NIH SUPPORT:*

1. U10EY023207 (Bressler) 02/01/14 – 12/31/18 up to 1.24 calendar  
National Eye Institute via subcontract from Northwestern University  
Diabetic Retinopathy Clinical Research Network  
Purpose: Assist the DRCR Network Chair in all of the responsibilities of the Network Chair; continue to serve on Executive Committee, the Operations Group, most protocol development and primary outcome manuscript committees, the Scientific Advisory Committee, and other committees as deemed necessary by the Operations Group, the Executive Committee, the Coordinating Center, or the Network Chair. Continue to back-up the Network Chair regarding interactions with regulatory agencies such as the FDA and CMS, industry collaborations, the NIDDK, the NEI, and Foundations such as the Juvenile Diabetes Research Foundation.
2. Diabetic Retinopathy Clinical Research Network: Network Chair's Office.  
NIH Grant  
Network Chair Elect (2005); Network Chair 2006 – 2012; 40% effort  
Project Period: 01/01/05 – 12/31/13  
Purpose: To serve as Chair of a network of clinical studies on diabetic retinopathy within a network of clinical centers, serving as Principal Investigator of the Network Chair's Office. See [www.drcr.net](http://www.drcr.net) for complete public information.
3. Submacular Surgery Trials: Study Chairman's Office Grant  
NIH Grant - 1 U10 EY11547-01  
Principal Investigator (*and Study Chairman*) – Up to 20% effort and support  
Project Period: 9/30/96 - 4/30/05  
Purpose: Multicenter randomized clinical trials designed to determine if submacular surgery can reduce the risk of visual loss in patients with choroidal neovascularization due to age-related macular degeneration (the leading cause of severe visual loss in

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – November 1, 2018

people over 65 in the United States and Western World), the ocular histoplasmosis syndrome or idiopathic causes.

4. Submacular Surgery Trials (SST) Pathology Center  
NIH Grant -1 U10 EY 12662-01  
Consultant – 2% effort  
Project Period: 8/99 - 7/05  
Purpose: To evaluate the clinicopathologic correlations of choroidal neovascularization structure and biochemistry from patients in comparison to their pre-surgery vision data, color fundus photographs, fluorescein angiograms, and visual outcomes. Additionally, post-mortem examination of eyes from patients enrolled in the SST will enable correlation of tissue changes in both operated and unoperated eyes with clinical data.
5. Age-Related Geographic Atrophy  
NIH Grant -2 R01 EY0D08522-06A1  
Co-Principal Investigator - 5% effort and support  
Project Period: 9/30/98-9/29/00  
Purpose: To determine natural history of patients with geographic atrophy from age-related macular degeneration to determine risk factors for visual loss and potential patient groups for interventional trials.
6. Application of Non Invasive Retinal Thickness  
NIH Grant - R01 EY06976-08A1  
Co-Principal Investigator - 5% effort and support  
Project Period: 7/1/94-7/1/99  
Purpose: Study the relationship between retinal thickness, measured by a novel optical technique, and the natural history and effect of laser treatment on diabetic macular edema.
7. Effect of Cataract & Age-Related Maculopathy on Vision  
NIH Grant - R01 EY06380-09  
Co-Investigator - 4% effort and support  
Project Period: 1/1/95-3/31/99  
Purpose: Develop a set of tools that will allow one to determine the potential benefits of cataract surgery in patients with age-related macular degeneration.
8. CMV Retinitis and Viral Drug Resistance  
NIH Grant - 1R01 EY05952  
Co-Investigator - 9% effort and support  
Project Period: 7/1/93-6/30/98  
Purpose: Epidemiologic study to determine the incidence and prevalence of resistant cytomegalovirus (CMV) in patients treated for CMV retinitis, as well as risk factors for its development.
9. Geographic Atrophy Study  
NIH Grant - EY08552-01

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – November 1, 2018

Co-Investigator - 4% effort and support  
Project Period: 03/01/92-02/28/97  
Purpose: 5-Year natural history study of progressive loss of central vision due to geographic atrophy.

10. Submacular Surgery Trials Planning Grant  
NIH Grant - R21 EY10823-01  
Principal Investigator (*Study Chairman*) - 10% effort  
Project Period: 1/1/95 - 3/31/96  
Purpose: To obtain support for activities required to plan and organize a multicenter study evaluating the role of submacular surgery in age-related macular degeneration and the ocular histoplasmosis syndrome.

11. Macular Photocoagulation Study Reading Center  
NIH Grant - EY05958-09  
Principal Investigator - 20% effort and support  
Project Period: 9/30/85 - 3/31/95  
Purpose: Evaluate fundus photographs and angiograms of all participants in the Macular Photocoagulation Study; collaborate with Coordinating Center.

12. Macular Photocoagulation Study:  
NIH Grant EY02556-12  
Principal Investigator - 5% effort and support  
Project Period: 1/1/79 - 12/31/93  
Purpose: Direct the clinical center at Wilmer randomizing patients to laser treatment or no treatment in the Macular Photocoagulation Study.

13. Follow-up Study of Eye Disease in a Cohort of Chesapeake Bay Watermen  
NIH Grant EY08776-01  
Co-investigator - 10% effort and support  
Project Period: 07/01/90 - 12/30/92  
Purpose: Longitudinal evaluation of cataract and macular degeneration in a population-based study.

---

## OTHER SUPPORT

**Note: Total effort is never 100%; several institutional service agreements have a maximum allowed amount, but might be utilized anywhere from 0% to that total amount in a given month.**

### ACTIVE

No Identifier (Bressler) Novartis Pharma AG <i>Institutional Service Agreement</i>	1/011/03 - 06/30/19 up to 1.94 calendar
--	---

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – November 1, 2018

Purpose: To serve, on behalf of the Johns Hopkins University School of Medicine, as a researcher in the design and implementation and interpretation of clinical research in the management of retinal diseases.

N01EY12113 (Bressler) 10/01/04 - 06/30/19 up to .12 calendar

Subcontract: Emmes Corp.

NIH/NEI

*NEI Data and Safety Monitoring*

*Committee—Chair*

Purpose: To chair Data and Safety Monitoring Committee for human subjects trials directed by the National Eye Institute intramural program.

No Identifier (Bressler) 01/01/06 –06/30/2016 up to .30 calendar

Regeneron Pharmaceuticals Inc. (RPI)

*Institutional Service Agreement*

Purpose: To serve, on behalf of the Johns Hopkins University School of Medicine, as a researcher in the design and implementation and interpretation of clinical research in the management of retinal diseases.

No Identifier (Bressler) 07/01/12 – 06/30/19 up to .52 calendar

Bayer

*Institutional Service Agreement*

Purpose: To serve, on behalf of the Johns Hopkins University School of Medicine, as a researcher in the design and implementation and interpretation of clinical research in the management of retinal diseases.

No Identifier (Bressler) 01/01/09 - 06/30/2019 up to 3.33 calendar

Genentech, Inc.

*Institutional Service Agreement*

Purpose: To serve, on behalf of the Johns Hopkins University School of Medicine, as a researcher in the design and implementation of clinical research in the management of retinal diseases, with specific reference to quality of life outcomes as well as treatment of geographic atrophy in age-related macular degeneration.

No Identifier (Bressler) 08/11/2014 – 06/30/2017 up to .48 calendar

Lumenis, Inc.

*Institutional Service Agreement*

Purpose: To serve, on behalf of the Johns Hopkins University School of Medicine, as a researcher in the design and implementation and interpretation of clinical research in the management of retinal diseases.

OVERLAP

None



**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – November 1, 2018

## EDITORIAL ROLES

Editor-in-Chief        *JAMA Ophthalmology* 2013 to present  
Editorial Board        *The JAMA Network Editorial Board* 2013 to present

### *Completed Editorial Boards:*

- 1991-1994: Section Editor (Reviews in Medicine), *Survey of Ophthalmology*
- 1995-2000: *The Wilmer Retina Update*, Editor-in-Chief (and Founding Editor)
- 1994-2013: Editorial Board: *JAMA Ophthalmology* (formerly *Archives of Ophthalmology* until December 2012, and Past Editor of *Controversies Section*)
- 1995-2013: Editorial Board: RETINA
- 2012-2013: Editorial Board: RETINA Cases and Brief Reports

---

## NATIONAL ADVISORY ROLES

### Current

- Ophthalmic Devices Panel of the Medical Devices Advisory Committee for the Center for Devices and Radiologic Health, Food and Drug Administration: 2000 – 2018 (Chair: 2008 - 2010)
- Chair, Data and Safety Monitoring Committee, National Eye Institute Intramural Program of National Institutes of Health: 2003 – 2018
- EDIC Observational Study Monitoring Board (OSMB) for the Epidemiology of Diabetes Interventions and Complications (EDIC) study: 2011 – 2018

### Past

- **Scientific Advisor:** NEI Research for Macular Degeneration: February 1990 - December 1990.
- **Consultant** - American Academy of Ophthalmology Preferred Practice Pattern for Macular Degeneration – 1990 to 1994
- **Ad Hoc Reviewer** - National Eye Institute - Study Sections – 1993 to present
- **Editor** - Basic and Clinical Science Course - Retina Section - American Academy of Ophthalmology - 1994-1998
- **Scientific Advisory Council: The Macula Foundation, Inc.**- 2002 – present
- **Scientific Advisor** - American Federation of Aging Research - 1992-1997
- **National Eye Institute (NEI) Special Emphasis Panel Review Committee** – member: 1997, 1998, 2001, 2003
- **U.S. Pharmacopeia Expert Committee** - Member, 2000 – 2005, 2005-2010
- **Carotene in Age-Related Eye Disease Study (CAREDS) Scientific Advisory Board** for National Eye Institute – 2002 – 2010
- **SCORE Advisory Group Member** – National Eye Institute: 2003 – 2008
- **Member, Data and Safety Monitoring Committee, National Eye Institute Intramural Program of National Institutes of Health** – 2002

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – November 1, 2018

- **Testimony before U.S. House of Representatives subcommittees, Senate subcommittees**, as well as staffers for U.S. House or U.S. Senate – various years from 2008 through 2014

---

**PROFESSIONAL SOCIETIES AND SERVICE TO PROFESSIONAL SOCIETIES**

- 1981-2014 **Association for Research in Vision and Ophthalmology**  
1995-1998 Program Committee (Chairman of Program Committee in 1998)  
1998-2002 Exhibits Committee (Chairman 2002)
- 1987-2014 **American Medical Association**
- 1987-2014 **American Academy of Ophthalmology**  
1994-1997 Editor, Basic and Clinical Science Course: *Retina Section*  
1990-2004 Consultant, Preferred Practice Patterns  
2003-2005 Committee on Aging
- 1990-2005 **Macula Society**  
1996-2002 Member, *Executive Committee*  
1996-2002 Chairman, *Program Committee*  
1994-1997 Member, *Research Committee*  
2008-2012 Macula Society Representative to American Academy of Ophthalmology Council  
2011-2012 Officer, Secretary  
2012-2013 Officer, President-elect  
2013-2014 Officer, President  
2014-2015 Office, Past President
- 1993-2014 **Retina Society**
- 1997-2014 **Society for Clinical Trials**  
1998-2002 Member, *Development Committee*
- 1998-2014 **Club Jules Gonin**
- 1998-2014 **American Society of Retina Specialists**  
2005 Chair, *Ad hoc* Leadership Committee  
2012 Co-chair, Vision 20/20  
2012 Founding editor: Retina Image Bank

---

**CLINICAL ACTIVITIES**

National and international referral practice specializing in the management of medical retinal disease (e.g., diabetic retinopathy, age-related macular degeneration, retinal vein occlusions),

**NEIL M. BRESSLER, M.D.**  
CURRICULUM VITAE – November 1, 2018

with specific reference to treatments for these conditions as well as designing and directing clinical trials evaluating new managements of these diseases.

---

**ADMINISTRATIVE RESPONSIBILITIES**

*UNIVERSITY SCHOOL OF MEDICINE ACTIVITIES*

- Associate Professor Promotions Committee (1994 - 1998)
- Chair, Dean's Committee on Outside Interests (2002 – present; Chair since 2006)
- Chair, Continuing Medical Education Advisory Board (2014 – 2015)

*DEPARTMENTAL ACTIVITIES*

- Clinical Practice Advisory Committee (1989 - present)
- Chair, Subcommittee on Electronic Patient Record for Wilmer Institute. (1995 -1997)
- Resident Education Committee: Serve in an advisory role to the Chief Resident to identify educational needs of the residency program, including the core curriculum. (1993 -1997)
- Chair, Wilmer Imaging Committee (2001- 2003)

*DIVISIONAL ACTIVITIES*

- **Chief, Retina Division (2005-2018):** One of the largest university-based retina divisions in the world with 18 full-time clinical faculty (6 assistant professors, 4 associate professors, 8 professors including 7 endowed professorships among the 17 faculty) with additional basic science faculty reporting to the clinical faculty with over 40,000 visits at Johns Hopkins Hospital and 5 satellite locations
- Head of Retinal Fellowship Program (1989 to 2007).
- Participation in training of over 100 residents and 65 retina fellows and numerous additional medical students and clinical research fellows.

---

**OTHER OUTSIDE ACTIVITIES**

**Board of Trustees,** Interlochen Center for the Arts, Interlochen, Michigan – 2007 to 2015.  
**Vice-Chair:** 2013 – 2015